{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:38:38Z","timestamp":1792550318839,"version":"4.5.0"},"reference-count":413,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01856-w","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:49:33Z","timestamp":1792504173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions"],"prefix":"10.1186","volume":"19","author":[{"given":"Huali","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuquan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"1","key":"1856_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","volume":"27","author":"K Ganesh","year":"2021","unstructured":"Ganesh K, Massagu\u00e9 J. Targeting metastatic cancer. Nat Med. 2021;27(1):34\u201344. https:\/\/doi.org\/10.1038\/s41591-020-01195-4.","journal-title":"Nat Med"},{"issue":"3","key":"1856_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clinicians. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clinicians"},{"issue":"12","key":"1856_CR3","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1002\/cam4.2474","volume":"8","author":"H Dillek\u00e5s","year":"2019","unstructured":"Dillek\u00e5s H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019;8(12):5574\u201376. https:\/\/doi.org\/10.1002\/cam4.2474.","journal-title":"Cancer Med"},{"issue":"1","key":"1856_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-023-00353-4","volume":"7","author":"FA Zeineddine","year":"2023","unstructured":"Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precis Onc. 2023;7(1):1\u20139. https:\/\/doi.org\/10.1038\/s41698-023-00353-4.","journal-title":"npj Precis. Onc"},{"issue":"11","key":"1856_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41416-019-0601-8","volume":"121","author":"TH Beckham","year":"2019","unstructured":"Beckham TH, Leeman JE, Xie P, Li X, Goldman DA, Zhang Z, et al. Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy. Br J Cancer. 2019;121(11):897\u2013903. https:\/\/doi.org\/10.1038\/s41416-019-0601-8.","journal-title":"Br J Cancer"},{"issue":"4","key":"1856_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/843214","volume":"2014","author":"A Sandru","year":"2014","unstructured":"Sandru A, Panaitescu E, Voinea S, Bolovan M, Stanciu A, Cinca S, et al. Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma. J Skin Cancer. 2014;2014(4):1\u20135. https:\/\/doi.org\/10.1155\/2014\/843214.","journal-title":"J Skin Cancer"},{"issue":"1","key":"1856_CR7","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41467-024-45307-x","volume":"15","author":"K Mani","year":"2024","unstructured":"Mani K, Deng D, Lin C, Wang M, Hsu ML, Zaorsky NG. Causes of death among people living with metastatic cancer. Nat Commun. 2024;15(1):1519. https:\/\/doi.org\/10.1038\/s41467-024-45307-x.","journal-title":"Nat Commun"},{"issue":"4","key":"1856_CR8","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/2159-8290.CD-21-0010","volume":"11","author":"J Massagu\u00e9","year":"2021","unstructured":"Massagu\u00e9 J, Ganesh K. Metastasis-initiating cells and ecosystems. Cancer Discov. 2021;11(4):971\u201394. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0010.","journal-title":"Cancer Discov"},{"issue":"8","key":"1856_CR9","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger S, Jiang Q, Ganesh K. Metastasis. Cell. 2023;186(8):1564\u201379. https:\/\/doi.org\/10.1016\/j.cell.2023.03.003.","journal-title":"Cell"},{"issue":"3","key":"1856_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41568-021-00427-0","volume":"22","author":"F Weiss","year":"2022","unstructured":"Weiss F, Lauffenburger D, Friedl P. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. Nat Rev Cancer. 2022;22(3):157\u201373. https:\/\/doi.org\/10.1038\/s41568-021-00427-0.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1856_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41568-026-00928-w","volume":"26","author":"JA Aguirre-Ghiso","year":"2026","unstructured":"Aguirre-Ghiso JA, Bravo-Cordero JJ, Guo W, Lauvau G, Sosa MS. The sleeping threat: targeting cancer dormancy to transform metastasis therapy. Nat Rev Cancer. Published online April 24, 2026;26(7):513\u201333. https:\/\/doi.org\/10.1038\/s41568-026-00928-w.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"1856_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41568-020-00300-6","volume":"20","author":"CA Klein","year":"2020","unstructured":"Klein CA. Cancer progression and the invisible phase of metastatic colonization. Nat Rev Cancer. 2020;20(11):681\u201394. https:\/\/doi.org\/10.1038\/s41568-020-00300-6.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1856_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"JC Marine","year":"2020","unstructured":"Marine JC, Dawson SJ, Dawson MA. Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020;20(12):743\u201356. https:\/\/doi.org\/10.1038\/s41568-020-00302-4.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"1856_CR14","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","volume":"16","author":"M Mikubo","year":"2021","unstructured":"Mikubo M, Inoue Y, Liu G, Tsao MS. Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J Thorac Oncol. 2021;16(11):1798\u2013809. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.017.","journal-title":"J Thorac Oncol"},{"issue":"6282","key":"1856_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1126\/science.aaf2784","volume":"352","author":"S Turajlic","year":"2016","unstructured":"Turajlic S, Swanton C. Metastasis as an evolutionary process. Science. 2016;352(6282):169\u201375. https:\/\/doi.org\/10.1126\/science.aaf2784.","journal-title":"Science"},{"issue":"4","key":"1856_CR16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","volume":"168","author":"AW Lambert","year":"2017","unstructured":"Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670\u201391. https:\/\/doi.org\/10.1016\/j.cell.2016.11.037.","journal-title":"Cell"},{"issue":"7547","key":"1856_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353\u201357. https:\/\/doi.org\/10.1038\/nature14347.","journal-title":"Nature"},{"issue":"7","key":"1856_CR18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/ng.3573","volume":"48","author":"A McPherson","year":"2016","unstructured":"McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet. 2016;48(7):758\u201367. https:\/\/doi.org\/10.1038\/ng.3573.","journal-title":"Nat Genet"},{"issue":"6","key":"1856_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrclinonc.2011.64","volume":"8","author":"E Comen","year":"2011","unstructured":"Comen E, Norton L, Massagu\u00e9 J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011;8(6):369\u201377. https:\/\/doi.org\/10.1038\/nrclinonc.2011.64.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"1856_CR20","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","volume":"139","author":"MY Kim","year":"2009","unstructured":"Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH-F, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315\u201326. https:\/\/doi.org\/10.1016\/j.cell.2009.11.025.","journal-title":"Cell"},{"issue":"11","key":"1856_CR21","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41416-025-03181-4","volume":"133","author":"HJ Lee","year":"2025","unstructured":"Lee HJ, Lee JH, Kang J, Kim K, Cho Y, Park J, et al. Single-cell multiomic modelling of early metastatic events promoted by the extracellular matrix. Br J Cancer. 2025;133(11):1708\u201319. https:\/\/doi.org\/10.1038\/s41416-025-03181-4.","journal-title":"Br J Cancer"},{"issue":"2","key":"1856_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccell.2020.06.012","volume":"38","author":"ND Marjanovic","year":"2020","unstructured":"Marjanovic ND, Hofree M, Chan JE, Canner D, Wu K, Trakala M, et al. Emergence of a high-plasticity cell state during lung cancer evolution. Cancer Cell. 2020;38(2):229\u201346.e13. https:\/\/doi.org\/10.1016\/j.ccell.2020.06.012.","journal-title":"Cancer Cell"},{"issue":"7702","key":"1856_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-018-0040-3","volume":"556","author":"I Pastushenko","year":"2018","unstructured":"Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, et al. Identification of the tumour transition states occurring during EMT. Nature. 2018;556(7702):463\u201368. https:\/\/doi.org\/10.1038\/s41586-018-0040-3.","journal-title":"Nature"},{"key":"1856_CR24","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2147\/ITT.S567643","volume":"14","author":"X Li","year":"2025","unstructured":"Li X, Qin X, Shi K, Lu G, Tian G, Chen Y, et al. Integrative spatial transcriptomics and experimental validation reveal UBC-mediated EMT associated with immune evasion in hepatocellular carcinoma. ImmunoTargets Ther. 2025;14:1437\u201354. https:\/\/doi.org\/10.2147\/ITT.S567643.","journal-title":"ITT"},{"key":"1856_CR25","doi-asserted-by":"publisher","first-page":"217880","DOI":"10.1016\/j.canlet.2025.217880","volume":"629","author":"C Yu","year":"2025","unstructured":"Yu C, Lu W, Wu J, Fang X, Wang X, Zhang G, et al. Liver metastasis or peritoneal metastasis: single-cell RNA sequencing reveals the organotropism in colorectal cancer is driven by distinct partial-EMT processes. Cancer Lett. 2025;629:217880. https:\/\/doi.org\/10.1016\/j.canlet.2025.217880.","journal-title":"Cancer Lett"},{"issue":"8","key":"1856_CR26","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.ccell.2021.05.005","volume":"39","author":"KP Simeonov","year":"2021","unstructured":"Simeonov KP, Byrns CN, Clark ML, Norgard RJ, Martin B, Stanger BZ, et al. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell. 2021;39(8):1150\u201362.e9. https:\/\/doi.org\/10.1016\/j.ccell.2021.05.005.","journal-title":"Cancer Cell"},{"issue":"1","key":"1856_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12967-025-06236-5","volume":"23","author":"Y Lu","year":"2025","unstructured":"Lu Y, Chen Y, Wang Z, Shen H, Xu L, Huang C, et al. Single-cell and spatial transcriptome profiling reveal CTHRC1 + fibroblasts promote EMT through WNT5A signaling in colorectal cancer. J Transl Med. 2025;23(1):282. https:\/\/doi.org\/10.1186\/s12967-025-06236-5.","journal-title":"J Transl Med"},{"issue":"1","key":"1856_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cell.2013.06.005","volume":"154","author":"CL Chaffer","year":"2013","unstructured":"Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer C, Reinhardt F, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013;154(1):61\u201374. https:\/\/doi.org\/10.1016\/j.cell.2013.06.005.","journal-title":"Cell"},{"key":"1856_CR29","doi-asserted-by":"publisher","unstructured":"Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. Embo J. 2021;40(18):EMBJ2021108647. https:\/\/doi.org\/10.15252\/embj.2021108647.","DOI":"10.15252\/embj.2021108647"},{"issue":"1","key":"1856_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-pathol-020117-043854","volume":"13","author":"V Mittal","year":"2018","unstructured":"Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol Mech Dis. 2018;13(1):395\u2013412. https:\/\/doi.org\/10.1146\/annurev-pathol-020117-043854.","journal-title":"Annu. Rev. Pathol. Mech. Dis"},{"issue":"2","key":"1856_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.celrep.2014.12.032","volume":"10","author":"JM Schmidt","year":"2015","unstructured":"Schmidt JM, Panzilius E, Bartsch HS, Irmler M, Beckers J, Kari V, et al. Stem-cell-like properties and epithelial plasticity arise as stable traits after transient Twist1 activation. Cell Rep. 2015;10(2):131\u201339. https:\/\/doi.org\/10.1016\/j.celrep.2014.12.032.","journal-title":"Cell Rep"},{"issue":"21","key":"1856_CR32","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1158\/0008-5472.CAN-14-0923","volume":"74","author":"HD Tran","year":"2014","unstructured":"Tran HD, Luitel K, Kim M, Zhang K, Longmore GD, Tran DD. Transient SNAIL1 expression is necessary for metastatic competence in breast cancer. Cancer Res. 2014;74(21):6330\u201340. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0923.","journal-title":"Cancer Res"},{"issue":"7579","key":"1856_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature16064","volume":"527","author":"X Zheng","year":"2015","unstructured":"Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525\u201330. https:\/\/doi.org\/10.1038\/nature16064.","journal-title":"Nature"},{"issue":"7579","key":"1856_CR34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature15748","volume":"527","author":"KR Fischer","year":"2015","unstructured":"Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong STC, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527(7579):472\u201376. https:\/\/doi.org\/10.1038\/nature15748.","journal-title":"Nature"},{"issue":"7930","key":"1856_CR35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41586-022-05242-7","volume":"610","author":"P Karras","year":"2022","unstructured":"Karras P, Bordeu I, Pozniak J, Nowosad A, Pazzi C, Van Raemdonck N, et al. A cellular hierarchy in melanoma uncouples growth and metastasis. Nature. 2022;610(7930):190\u201398. https:\/\/doi.org\/10.1038\/s41586-022-05242-7.","journal-title":"Nature"},{"issue":"7350","key":"1856_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP\/TAZ in mechanotransduction. Nature. 2011;474(7350):179\u201383. https:\/\/doi.org\/10.1038\/nature10137.","journal-title":"Nature"},{"issue":"8047","key":"1856_CR37","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41586-024-08150-0","volume":"637","author":"A Moorman","year":"2025","unstructured":"Moorman A, Benitez EK, Cambuli F, Jiang Q, Mahmoud A, Lumish M, et al. Progressive plasticity during colorectal cancer metastasis. Nature. 2025;637(8047):947\u201354. https:\/\/doi.org\/10.1038\/s41586-024-08150-0.","journal-title":"Nature"},{"issue":"9","key":"1856_CR38","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41422-025-01139-y","volume":"35","author":"L Xiong","year":"2025","unstructured":"Xiong L, Xu Y, Gao Z, Shi J, Wang Y, Wang X, et al. A patient-derived organoid model captures fetal-like plasticity in colorectal cancer. Cell Res. 2025;35(9):642\u201355. https:\/\/doi.org\/10.1038\/s41422-025-01139-y.","journal-title":"Cell Res"},{"issue":"10","key":"1856_CR39","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/cells8101118","volume":"8","author":"CY Loh","year":"2019","unstructured":"Loh CY, Chai JY, Tang TF, Wong W, Sethi G, Shanmugam M, et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):1118. https:\/\/doi.org\/10.3390\/cells8101118.","journal-title":"Cells"},{"issue":"8","key":"1856_CR40","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1074\/jbc.REV119.007759","volume":"295","author":"M Janiszewska","year":"2020","unstructured":"Janiszewska M, Primi MC, Izard T. Cell adhesion in cancer: beyond the migration of single cells. J Biol Chem. 2020;295(8):2495\u2013505. https:\/\/doi.org\/10.1074\/jbc.REV119.007759.","journal-title":"J Biol Chem"},{"issue":"7","key":"1856_CR41","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrm2720","volume":"10","author":"P Friedl","year":"2009","unstructured":"Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol. 2009;10(7):445\u201357. https:\/\/doi.org\/10.1038\/nrm2720.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"1856_CR42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.devcel.2008.10.002","volume":"15","author":"A Aman","year":"2008","unstructured":"Aman A, Piotrowski T. Wnt\/\u03b2-catenin and Fgf signaling control collective cell migration by restricting chemokine receptor expression. Dev Cell. 2008;15(5):749\u201361. https:\/\/doi.org\/10.1016\/j.devcel.2008.10.002.","journal-title":"Dev Cell"},{"issue":"1","key":"1856_CR43","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1146\/annurev-cellbio-111315-125227","volume":"32","author":"A Castro-Castro","year":"2016","unstructured":"Castro-Castro A, Marchesin V, Monteiro P, Lodillinsky C, Ross\u00e9 C, Chavrier P. Cellular and molecular mechanisms of MT1-MMP-Dependent cancer cell invasion. Annu. Rev. Cell Dev. Biol. 2016;32(1):555\u201376. https:\/\/doi.org\/10.1146\/annurev-cellbio-111315-125227.","journal-title":"Annu. Rev. Cell Dev. Biol"},{"issue":"19","key":"1856_CR44","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1101\/gad.1451806","volume":"20","author":"K Hotary","year":"2006","unstructured":"Hotary K, Li XY, Allen E, Stevens SL, Weiss SJ. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev. 2006;20(19):2673\u201386. https:\/\/doi.org\/10.1101\/gad.1451806.","journal-title":"Genes Dev"},{"issue":"3","key":"1856_CR45","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184(3):792\u2013809.e23. https:\/\/doi.org\/10.1016\/j.cell.2021.01.010.","journal-title":"Cell"},{"issue":"1","key":"1856_CR46","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11(1):5120. https:\/\/doi.org\/10.1038\/s41467-020-18794-x.","journal-title":"Nat Commun"},{"issue":"7","key":"1856_CR47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","volume":"3","author":"D Lavie","year":"2022","unstructured":"Lavie D, Ben-Shmuel A, Erez N, Scherz-Shouval R. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 2022;3(7):793\u2013807. https:\/\/doi.org\/10.1038\/s43018-022-00411-z.","journal-title":"Nat Cancer"},{"issue":"1","key":"1856_CR48","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41467-023-35793-w","volume":"14","author":"JM Houthuijzen","year":"2023","unstructured":"Houthuijzen JM, de Bruijn R, van der Burg E, Drenth AP, Wientjens E, Filipovic T, et al. CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer. Nat Commun. 2023;14(1):183. https:\/\/doi.org\/10.1038\/s41467-023-35793-w.","journal-title":"Nat Commun"},{"issue":"12","key":"1856_CR49","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/ncb1658","volume":"9","author":"C Gaggioli","year":"2007","unstructured":"Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol. 2007;9(12):1392\u2013400. https:\/\/doi.org\/10.1038\/ncb1658.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"1856_CR50","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.ccell.2025.09.001","volume":"43","author":"X Chen","year":"2025","unstructured":"Chen X, Zhou Z, Xie L, Qiao K, Jia Y, Liu S, et al. Single-cell resolution spatial analysis of antigen-presenting cancer-associated fibroblast niches. Cancer Cell. 2025;43(12):2224\u201340.e9. https:\/\/doi.org\/10.1016\/j.ccell.2025.09.001.","journal-title":"Cancer Cell"},{"issue":"11","key":"1856_CR51","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1172\/JCI129249","volume":"130","author":"JJ Northey","year":"2020","unstructured":"Northey JJ, Barrett AS, Acerbi I, Hayward M-K, Talamantes S, Dean IS, et al. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217. J Clin Invest. 2020;130(11):5721\u201337. https:\/\/doi.org\/10.1172\/JCI129249.","journal-title":"J Clin Invest"},{"issue":"19","key":"1856_CR52","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-15-0226","volume":"21","author":"J Lee","year":"2015","unstructured":"Lee J, Condello S, Yakubov B, Emerson R, Caperell-Grant A, Hitomi K, et al. Tissue transglutaminase mediated tumor\u2013stroma interaction promotes pancreatic cancer progression. Clin Cancer Res. 2015;21(19):4482\u201393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0226.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1856_CR53","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ncb3157","volume":"17","author":"SC Wei","year":"2015","unstructured":"Wei SC, Fattet L, Tsai JH, Guo Y, Pai VH, Majeski HE, et al. Matrix stiffness drives epithelial\u2013mesenchymal transition and tumour metastasis through a TWIST1\u2013G3BP2 mechanotransduction pathway. Nat Cell Biol. 2015;17(5):678\u201388. https:\/\/doi.org\/10.1038\/ncb3157.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1856_CR54","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13046-025-03510-8","volume":"44","author":"S Hu","year":"2025","unstructured":"Hu S, Ding M, Lou J, Qin J, Chen Y, Liu Z, et al. COL10A1+ fibroblasts promote colorectal cancer metastasis and M2 macrophage polarization with pan-cancer relevance. J Exp Clin Cancer Res: CR. 2025;44(1):243. https:\/\/doi.org\/10.1186\/s13046-025-03510-8.","journal-title":"J Exp Clin Cancer Res: CR"},{"issue":"1","key":"1856_CR55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1158\/0008-5472.CAN-24-4916","volume":"86","author":"S Liu","year":"2026","unstructured":"Liu S, Zhang Z, Wang Z, Liu C, Liang G, Xu T, et al. SPP1 drives colorectal cancer liver metastasis and immunotherapy resistance by stimulating CXCL12 production in cancer-associated fibroblasts. Cancer Res. 2026;86(1):58\u201379. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-4916.","journal-title":"Cancer Res"},{"issue":"1","key":"1856_CR56","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12967-026-07853-4","volume":"24","author":"S Xie","year":"2026","unstructured":"Xie S, Li J, Heng S, Xiao J, Chen J, Qi X. Integrated single-cell and spatial transcriptomics uncover SPP1\u207a and HLA-DRB5\u207a macrophages as key modulators of the immune microenvironment in colorectal cancer liver metastasis. J Transl Med. 2026;24(1):370. https:\/\/doi.org\/10.1186\/s12967-026-07853-4.","journal-title":"J Transl Med"},{"key":"1856_CR57","doi-asserted-by":"publisher","unstructured":"Ding D, Li W, Ren J, Li Y, Jiang G, Liang R, et al. SPP1high macrophage-induced T-cell stress promotes colon cancer liver metastasis through SPP1\/CD44\/PI3K\/AKT signaling. J ImmunoTher Cancer. 2025;13(10):e012330. https:\/\/doi.org\/10.1136\/jitc-2025-012330.","DOI":"10.1136\/jitc-2025-012330"},{"key":"1856_CR58","doi-asserted-by":"publisher","unstructured":"Chang M, Feng M, Lei Y, Wang Y, Bai L, Wang Y. Integrated single-cell and spatial transcriptomic analysis reveals mCAF-SPP1\u207a macrophage-T cell crosstalk shaping immunosuppressive niches in colorectal cancer liver metastasis. J Transl Med. 24(1). https:\/\/doi.org\/10.1186\/s12967-026-07978-6. Published online March 10, 2026.","DOI":"10.1186\/s12967-026-07978-6"},{"key":"1856_CR59","doi-asserted-by":"publisher","unstructured":"Hu X, Shi W, Dong L, Huang L, Zhang X, Feng Y, et al. Decoding the cellular heterogeneity and malignant progression of human penile squamous cell carcinoma by single-cell RNA sequencing. Adv Sci (Weinh)Adv Sci. 2026;13(14):e03894. https:\/\/doi.org\/10.1002\/advs.202503894.","DOI":"10.1002\/advs.202503894"},{"issue":"10","key":"1856_CR60","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-10-4316","volume":"71","author":"PB Olkhanud","year":"2011","unstructured":"Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res. 2011;71(10):3505\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-4316.","journal-title":"Cancer Res"},{"issue":"14","key":"1856_CR61","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.1158\/0008-5472.CAN-08-4619","volume":"69","author":"PB Olkhanud","year":"2009","unstructured":"Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. 2009;69(14):5996\u20136004. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4619.","journal-title":"Cancer Res"},{"key":"1856_CR62","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.cytogfr.2023.08.002","volume":"74","author":"X Tian","year":"2023","unstructured":"Tian X, Wang T, Shen H, Wang S. Tumor microenvironment, histone modifications, and myeloid-derived suppressor cells. Cytokine Growth Factor Rev. 2023;74:108\u201321. https:\/\/doi.org\/10.1016\/j.cytogfr.2023.08.002.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"9","key":"1856_CR63","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nri3049","volume":"11","author":"A Zlotnik","year":"2011","unstructured":"Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11(9):597\u2013606. https:\/\/doi.org\/10.1038\/nri3049.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1856_CR64","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","volume":"18","author":"H Jia","year":"2025","unstructured":"Jia H, Chen X, Zhang L, Chen M. Cancer associated fibroblasts in cancer development and therapy. J Hematol Oncol. 2025;18(1):36. https:\/\/doi.org\/10.1186\/s13045-025-01688-0.","journal-title":"J Hematol Oncol"},{"key":"1856_CR65","doi-asserted-by":"publisher","unstructured":"Wang S, Hu H, Zeng W, Qin L, Chen X, Liao Z, et al. Targeting tumor stroma: current challenges and future directions. MedComm. 2026;7(5):e70763. https:\/\/doi.org\/10.1002\/mco2.70763.","DOI":"10.1002\/mco2.70763"},{"key":"1856_CR66","doi-asserted-by":"publisher","first-page":"114906","DOI":"10.1016\/j.intimp.2025.114906","volume":"160","author":"L Hou","year":"2025","unstructured":"Hou L, Jiang M, Li Y, Cheng J, Liu F, Han X, et al. Targeting SPP1+ macrophages via the SPP1-CD44 axis reveals a key mechanism of immune suppression and tumor progression in ovarian cancer. Int Immunopharmacol. 2025;160:114906. https:\/\/doi.org\/10.1016\/j.intimp.2025.114906.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"1856_CR67","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248\u201364. https:\/\/doi.org\/10.1016\/j.cell.2019.01.021.","journal-title":"Cell"},{"key":"1856_CR68","doi-asserted-by":"publisher","unstructured":"Du Y, Wang YR, Bao QY, Xu X-X, Xu C, Wang S, et al. Personalized vascularized tumor organoid-on-a-chip for tumor metastasis and therapeutic targeting assessment. Adv Mater. 2025;37(6):e2412815. https:\/\/doi.org\/10.1002\/adma.202412815.","DOI":"10.1002\/adma.202412815"},{"key":"1856_CR69","doi-asserted-by":"publisher","first-page":"599281","DOI":"10.3389\/fcell.2020.599281","volume":"8","author":"X Wang","year":"2020","unstructured":"Wang X, Bove AM, Simone G, Ma B. Molecular bases of VEGFR-2-Mediated physiological function and pathological role. Front Cell Dev Biol. 2020;8:599281. https:\/\/doi.org\/10.3389\/fcell.2020.599281.","journal-title":"Front Cell Dev Biol"},{"issue":"37","key":"1856_CR70","doi-asserted-by":"publisher","first-page":"39550","DOI":"10.18632\/oncotarget.6098","volume":"6","author":"Z Huang","year":"2015","unstructured":"Huang Z, Wu T, Liu AY, Ouyang G. Differentiation and transdifferentiation potentials of cancer stem cells. Oncotarget. 2015;6(37):39550\u201363. https:\/\/doi.org\/10.18632\/oncotarget.6098.","journal-title":"Oncotarget"},{"issue":"1","key":"1856_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-025-02279-w","volume":"24","author":"K Miao","year":"2025","unstructured":"Miao K, Zhang A, Yang X, Zhang Y, Lin A, Wang L, et al. Lymphatic system is the mainstream for breast cancer dissemination and metastasis revealed by single-cell lineage tracing. Mol Cancer. 2025;24(1):75. https:\/\/doi.org\/10.1186\/s12943-025-02279-w.","journal-title":"Mol Cancer"},{"issue":"1","key":"1856_CR72","doi-asserted-by":"publisher","first-page":"7442","DOI":"10.1038\/s41598-017-06637-7","volume":"7","author":"H Yan","year":"2017","unstructured":"Yan H, Zhang C, Wang Z, Tu T, Duan H, Luo Y, et al. CD146 is required for VEGF-C-induced lymphatic sprouting during lymphangiogenesis. Sci Rep. 2017;7(1):7442. https:\/\/doi.org\/10.1038\/s41598-017-06637-7.","journal-title":"Sci Rep"},{"issue":"5","key":"1856_CR73","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1182\/blood-2008-06-159343","volume":"112","author":"T Karpanen","year":"2008","unstructured":"Karpanen T, Alitalo K. VEGF-D: a modifier of embryonic lymphangiogenesis. Blood. 2008;112(5):1547\u201348. https:\/\/doi.org\/10.1182\/blood-2008-06-159343.","journal-title":"Blood"},{"issue":"2","key":"1856_CR74","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/84635","volume":"7","author":"SA Stacker","year":"2001","unstructured":"Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7(2):186\u201391. https:\/\/doi.org\/10.1038\/84635.","journal-title":"Nat Med"},{"issue":"44","key":"1856_CR75","doi-asserted-by":"publisher","first-page":"17406","DOI":"10.1073\/pnas.0703446104","volume":"104","author":"K Stoletov","year":"2007","unstructured":"Stoletov K, Montel V, Lester RD, Gonias SL, Klemke R. High-resolution imaging of the dynamic tumor cell\u2013vascular interface in transparent zebrafish. Proc Natl Acad Sci USA. 2007;104(44):17406\u201311. https:\/\/doi.org\/10.1073\/pnas.0703446104.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"1856_CR76","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1158\/2159-8290.CD-15-0012","volume":"5","author":"AS Harney","year":"2015","unstructured":"Harney AS, Arwert EN, Entenberg D, Wang Y, Guo P, Qian B-Z, et al. Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage\u2013derived VEGFA. Cancer Discov. 2015;5(9):932\u201343. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0012.","journal-title":"Cancer Discov"},{"issue":"14","key":"1856_CR77","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1182\/blood-2011-01-328716","volume":"118","author":"RL Huang","year":"2011","unstructured":"Huang RL, Teo Z, Chong HC, Zhu P, Tan MJ, Tan CK, et al. ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters. Blood. 2011;118(14):3990\u20134002. https:\/\/doi.org\/10.1182\/blood-2011-01-328716.","journal-title":"Blood"},{"issue":"26","key":"1856_CR78","doi-asserted-by":"publisher","first-page":"14608","DOI":"10.1073\/pnas.97.26.14608","volume":"97","author":"YS Chang","year":"2000","unstructured":"Chang YS, di Tomaso TE, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA. 2000;97(26):14608. https:\/\/doi.org\/10.1073\/pnas.97.26.14608.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1856_CR79","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc1092","volume":"3","author":"MJC Hendrix","year":"2003","unstructured":"Hendrix MJC, Seftor EA, Hess AR, Seftor REB. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. 2003;3(6):411\u201321. https:\/\/doi.org\/10.1038\/nrc1092.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1856_CR80","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.1158\/0008-5472.CAN-04-1853","volume":"65","author":"S Goswami","year":"2005","unstructured":"Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1\/epidermal growth factor paracrine loop. Cancer Res. 2005;65(12):5278\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1853.","journal-title":"Cancer Res"},{"issue":"10","key":"1856_CR81","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1038\/s41588-025-02341-9","volume":"57","author":"X Pei","year":"2025","unstructured":"Pei X, Liu Z, Tang L, Zhang J, He Y, Zhuang X, et al. Single-cell multi-omic and spatial profiling of esophageal squamous cell carcinoma reveals the immunosuppressive role of GPR116+ pericytes in cancer metastasis. Nat Genet. 2025;57(10):2494\u2013508. https:\/\/doi.org\/10.1038\/s41588-025-02341-9.","journal-title":"Nat Genet"},{"issue":"9","key":"1856_CR82","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7(9):987\u201389. https:\/\/doi.org\/10.1038\/nm0901-987.","journal-title":"Nat Med"},{"issue":"24","key":"1856_CR83","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301. https:\/\/doi.org\/10.1056\/NEJMoa1716948.","journal-title":"N Engl J Med"},{"key":"1856_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/306879","volume":"2012","author":"YN Kim","year":"2012","unstructured":"Kim YN, Koo KH, Sung JY, Yun UJ, Kim H. Anoikis Resistance: An Essential Prerequisite for Tumor Metastasis. Int J Cell Biol. 2012;2012:1\u201311. https:\/\/doi.org\/10.1155\/2012\/306879.","journal-title":"Int J Cell Biol"},{"issue":"5","key":"1856_CR85","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10585-022-10172-9","volume":"39","author":"SU Khan","year":"2022","unstructured":"Khan SU, Fatima K, Malik F. Understanding the cell survival mechanism of anoikis-resistant cancer cells during different steps of metastasis. Clin Exp Metastasis. 2022;39(5):715\u201326. https:\/\/doi.org\/10.1007\/s10585-022-10172-9.","journal-title":"Clin Exp Metastasis"},{"key":"1856_CR86","doi-asserted-by":"publisher","first-page":"216968","DOI":"10.1016\/j.canlet.2024.216968","volume":"593","author":"S Belli","year":"2024","unstructured":"Belli S, Esposito D, Ascione CM, Messina F, Napolitano F, Servetto A, et al. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4\/6 inhibitors in ER+ breast cancer. Cancer Lett. 2024;593:216968. https:\/\/doi.org\/10.1016\/j.canlet.2024.216968.","journal-title":"Cancer Lett"},{"issue":"8","key":"1856_CR87","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/ncb1026","volume":"5","author":"MJ Reginato","year":"2003","unstructured":"Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J, et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein bim to prevent anoikis. Nat Cell Biol. 2003;5(8):733\u201340. https:\/\/doi.org\/10.1038\/ncb1026.","journal-title":"Nat Cell Biol"},{"issue":"9","key":"1856_CR88","first-page":"3819","volume":"61","author":"G Li","year":"2001","unstructured":"Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 2001;61(9):3819\u201325.","journal-title":"Cancer Res"},{"issue":"21","key":"1856_CR89","doi-asserted-by":"publisher","first-page":"8115","DOI":"10.3390\/ijms21218115","volume":"21","author":"Y Xin","year":"2020","unstructured":"Xin Y, Li K, Yang M, Tan Y. Fluid shear stress induces EMT of circulating tumor cells via JNK signaling in favor of their survival during hematogenous dissemination. Int J Mol Sci. 2020;21(21):8115. https:\/\/doi.org\/10.3390\/ijms21218115.","journal-title":"IJMS"},{"issue":"2","key":"1856_CR90","doi-asserted-by":"publisher","first-page":"113005","DOI":"10.1016\/j.yexcr.2021.113005","volume":"411","author":"HJ Joo","year":"2022","unstructured":"Joo HJ, Chung GE, Han S, Ka HI, Soh SJ, Yang Y. Adapted suspension tumor cells rewire metabolic pathways for anchorage-independent survival through AKT activation. Exp Cell Res. 2022;411(2):113005. https:\/\/doi.org\/10.1016\/j.yexcr.2021.113005.","journal-title":"Exp Cell Res"},{"issue":"3","key":"1856_CR91","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1158\/2159-8290.CD-19-1500","volume":"11","author":"X Hong","year":"2021","unstructured":"Hong X, Roh W, Sullivan RJ, Wong KHK, Wittner BS, Guo H, et al. The lipogenic regulator SREBP2 induces transferrin in circulating melanoma cells and suppresses ferroptosis. Cancer Discov. 2021;11(3):678\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1500.","journal-title":"Cancer Discov"},{"key":"1856_CR92","doi-asserted-by":"publisher","first-page":"120738","DOI":"10.1016\/j.cca.2025.120738","volume":"580","author":"N Duggina","year":"2026","unstructured":"Duggina N, Mohan S, Sharif SH, Buddolla V. Metabolic and epigenetic reprogramming in circulating tumor cells: advances in liquid biopsy and cancer management. Clinica Acta. 2026;580:120738. https:\/\/doi.org\/10.1016\/j.cca.2025.120738.","journal-title":"Clinica Acta"},{"issue":"2","key":"1856_CR93","doi-asserted-by":"publisher","first-page":"116941","DOI":"10.1016\/j.celrep.2026.116941","volume":"45","author":"G Xu","year":"2026","unstructured":"Xu G, Li Y, Peng S, Zhao W, Xie T, Zheng M, et al. Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer. Cell Rep. 2026;45(2):116941. https:\/\/doi.org\/10.1016\/j.celrep.2026.116941.","journal-title":"Cell Rep"},{"issue":"12","key":"1856_CR94","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.7150\/jca.51849","volume":"12","author":"S Wang","year":"2021","unstructured":"Wang S, Lv Y, Zhou Y, Ling J, Wang H, Gu D, et al. Acidic extracellular pH induces autophagy to promote anoikis resistance of hepatocellular carcinoma cells via downregulation of miR-3663-3p. J Cancer. 2021;12(12):3418\u201326. https:\/\/doi.org\/10.7150\/jca.51849.","journal-title":"J Cancer"},{"issue":"8","key":"1856_CR95","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s43587-021-00098-4","volume":"1","author":"Y Aman","year":"2021","unstructured":"Aman Y, Schmauck-Medina T, Hansen M, Morimoto RI, Simon AK, Bjedov I, et al. Autophagy in healthy aging and disease. Nat Aging. 2021;1(8):634\u201350. https:\/\/doi.org\/10.1038\/s43587-021-00098-4.","journal-title":"Nat Aging"},{"issue":"3","key":"1856_CR96","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1091\/mbc.e07-10-1092","volume":"19","author":"C Fung","year":"2008","unstructured":"Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell. 2008;19(3):797\u2013806. https:\/\/doi.org\/10.1091\/mbc.e07-10-1092.","journal-title":"MBoC"},{"issue":"1","key":"1856_CR97","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13046-025-03617-y","volume":"45","author":"C Sanglier","year":"2026","unstructured":"Sanglier C, Cayrefourcq L, Alix-Panabi\u00e8res C. Reconstructing the metastatic journey: functional circulating tumor cells and disseminated tumor cells based models for translational oncology. J Exp Clin Cancer Res. 2026;45(1):46. https:\/\/doi.org\/10.1186\/s13046-025-03617-y.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"1856_CR98","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/biom11020130","volume":"11","author":"J Badia-Ramentol","year":"2021","unstructured":"Badia-Ramentol J, Linares J, G\u00f3mez-Llonin A, Calon A. Minimal residual disease, metastasis and immunity. Biomolecules. 2021;11(2):130. https:\/\/doi.org\/10.3390\/biom11020130.","journal-title":"Biomolecules"},{"issue":"11","key":"1856_CR99","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.trecan.2021.07.001","volume":"7","author":"E Schuster","year":"2021","unstructured":"Schuster E, Taftaf R, Reduzzi C, Albert MK, Romero-Calvo I, Liu H. Better together: circulating tumor cell clustering in metastatic cancer. Trends Cancer. 2021;7(11):1020\u201332. https:\/\/doi.org\/10.1016\/j.trecan.2021.07.001.","journal-title":"Trends Cancer"},{"issue":"4","key":"1856_CR100","doi-asserted-by":"publisher","first-page":"189384","DOI":"10.1016\/j.bbcan.2025.189384","volume":"1880","author":"D Bisht","year":"2025","unstructured":"Bisht D, Kumar V, Gupta S, Sachan M. Navigating circulating tumour cells and tumour microemboli: where we stand in bridging their molecular dynamics with clinical translation. Biochim et Biophys Acta (BBA) - Rev Cancer. 2025;1880(4):189384. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189384.","journal-title":"Biochim et Biophys Acta (BBA) - Rev Cancer"},{"issue":"4","key":"1856_CR101","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s10555-023-10124-z","volume":"42","author":"MM Nasr","year":"2023","unstructured":"Nasr MM, Lynch CC. How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy. Cancer Metastasis Rev. 2023;42(4):1133\u201346. https:\/\/doi.org\/10.1007\/s10555-023-10124-z.","journal-title":"Cancer Metastasis Rev"},{"issue":"18","key":"1856_CR102","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1073\/pnas.1524448113","volume":"113","author":"SH Au","year":"2016","unstructured":"Au SH, Storey BD, Moore JC, Tang Q, Chen Y-L, Javaid S, et al. Clusters of circulating tumor cells traverse capillary-sized vessels. Proc Natl Acad Sci USA. 2016;113(18):4947\u201352. https:\/\/doi.org\/10.1073\/pnas.1524448113.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1856_CR103","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/2159-8290.CD-18-0065","volume":"9","author":"X Liu","year":"2019","unstructured":"Liu X, Taftaf R, Kawaguchi M, Chang Y-F, Chen W, Entenberg D, et al. Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models. Cancer Discov. 2019;9(1):96\u2013113. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0065.","journal-title":"Cancer Discov"},{"key":"1856_CR104","doi-asserted-by":"publisher","unstructured":"Li K, Wu R, Zhou M, Tong H, Luo KQ. Desmosomal proteins of DSC2 and PKP1 promote cancer cells survival and metastasis by increasing cluster formation in circulatory system. Sci Adv. 2021;7(40):eabg7265. https:\/\/doi.org\/10.1126\/sciadv.abg7265.","DOI":"10.1126\/sciadv.abg7265"},{"issue":"1","key":"1856_CR105","doi-asserted-by":"publisher","first-page":"6150","DOI":"10.1038\/s41598-021-85743-z","volume":"11","author":"M Maeshiro","year":"2021","unstructured":"Maeshiro M, Shinriki S, Liu R, Nakachi Y, Komohara Y, Fujiwara Y, et al. Colonization of distant organs by tumor cells generating circulating homotypic clusters adaptive to fluid shear stress. Sci Rep. 2021;11(1):6150. https:\/\/doi.org\/10.1038\/s41598-021-85743-z.","journal-title":"Sci Rep"},{"issue":"1","key":"1856_CR106","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13058-018-0993-z","volume":"20","author":"G Kallergi","year":"2018","unstructured":"Kallergi G, Aggouraki D, Zacharopoulou N, Stournaras C, Georgoulias V, Martin SS. Evaluation of \u03b1-tubulin, detyrosinated \u03b1-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements. Breast Cancer Res. 2018;20(1):67. https:\/\/doi.org\/10.1186\/s13058-018-0993-z.","journal-title":"Breast Cancer Res"},{"issue":"21","key":"1856_CR107","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.3390\/cancers13215272","volume":"13","author":"M Lim","year":"2021","unstructured":"Lim M, Park S, Jeong HO, Park SH, Kumar S, Jang A, et al. Circulating tumor cell clusters are cloaked with platelets and correlate with poor prognosis in unresectable pancreatic cancer. Cancers (Basel). 2021;13(21):5272. https:\/\/doi.org\/10.3390\/cancers13215272.","journal-title":"Cancers (Basel)"},{"issue":"7745","key":"1856_CR108","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-019-0915-y","volume":"566","author":"BM Szczerba","year":"2019","unstructured":"Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019;566(7745):553\u201357. https:\/\/doi.org\/10.1038\/s41586-019-0915-y.","journal-title":"Nature"},{"issue":"9","key":"1856_CR109","doi-asserted-by":"publisher","first-page":"111298","DOI":"10.1016\/j.celrep.2022.111298","volume":"40","author":"T Pereira-Veiga","year":"2022","unstructured":"Pereira-Veiga T, Schneegans S, Pantel K, Wikman H. Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance. Cell Rep. 2022;40(9):111298. https:\/\/doi.org\/10.1016\/j.celrep.2022.111298.","journal-title":"Cell Rep"},{"key":"1856_CR110","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fcell.2018.00112","volume":"6","author":"JB McCarthy","year":"2018","unstructured":"McCarthy JB, El-Ashry D, Turley EA. Corrigendum: hyaluronan, cancer-associated fibroblasts and the tumor microenvironment in malignant progression. Front Cell Dev Biol. 2018;6:112. https:\/\/doi.org\/10.3389\/fcell.2018.00112.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"1856_CR111","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576\u201390. https:\/\/doi.org\/10.1016\/j.ccr.2011.09.009.","journal-title":"Cancer Cell"},{"issue":"2","key":"1856_CR112","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-11-1872","volume":"72","author":"T Placke","year":"2012","unstructured":"Placke T, \u00d6rgel M, Schaller M, Jung G, Rammensee H-G, Kopp H-G, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440\u201348. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1872.","journal-title":"Cancer Res"},{"issue":"3","key":"1856_CR113","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/HEP.0000000000000934","volume":"81","author":"Y Sun","year":"2025","unstructured":"Sun Y, Li T, Ding L, Wang J, Chen C, Liu T, et al. Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT. Hepatology. 2025;81(3):791\u2013807. https:\/\/doi.org\/10.1097\/HEP.0000000000000934.","journal-title":"Hepatology"},{"issue":"1","key":"1856_CR114","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-018-0145-8","volume":"6","author":"C Agnoletto","year":"2018","unstructured":"Agnoletto C, Minotti L, Brulle-Soumare L, Pasquali L, Galasso M, Corr\u00e0 F, et al. Heterogeneous expression of EPCAM in human circulating tumour cells from patient-derived xenografts. Biomark Res. 2018;6(1):31. https:\/\/doi.org\/10.1186\/s40364-018-0145-8.","journal-title":"Biomark Res"},{"issue":"1","key":"1856_CR115","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13058-015-0624-x","volume":"17","author":"G Kallergi","year":"2015","unstructured":"Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D, et al. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Res. 2015;17(1):113. https:\/\/doi.org\/10.1186\/s13058-015-0624-x.","journal-title":"Breast Cancer Res"},{"key":"1856_CR116","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.oraloncology.2018.12.002","volume":"89","author":"K Chikamatsu","year":"2019","unstructured":"Chikamatsu K, Tada H, Takahashi H, Kuwabara-Yokobori Y, Ishii H, Ida S, et al. Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma. Oral Oncol. 2019;89:34\u201339. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.12.002.","journal-title":"Oral Oncol"},{"key":"1856_CR117","doi-asserted-by":"publisher","unstructured":"Darga EP, Dolce EM, Fang F, Kidwell KM, Gersch CL, Kregel S, et al. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS One. 2021;16(11):e0260124. https:\/\/doi.org\/10.1371\/journal.pone.0260124.","DOI":"10.1371\/journal.pone.0260124"},{"key":"1856_CR118","doi-asserted-by":"publisher","unstructured":"Yf S, W L, Sp L, et al. Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. Nat Commun. 2021;12(1). https:\/\/doi.org\/10.1038\/s41467-021-24386-0.","DOI":"10.1038\/s41467-021-24386-0"},{"issue":"15","key":"1856_CR119","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","volume":"22","author":"C Alfaro","year":"2016","unstructured":"Alfaro C, Teijeira A, O\u00f1ate C, P\u00e9rez G, Sanmamed MF, Andueza MP, et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 2016;22(15):3924\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2463.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1856_CR120","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1158\/0008-5472.CAN-20-3595","volume":"81","author":"PA Osmulski","year":"2021","unstructured":"Osmulski PA, Cunsolo A, Chen M, Qian Y, Lin C-L, Hung C-N, et al. Contacts with macrophages promote an aggressive nanomechanical phenotype of circulating tumor cells in prostate cancer. Cancer Res. 2021;81(15):4110\u201323. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3595.","journal-title":"Cancer Res"},{"issue":"8","key":"1856_CR121","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.3390\/ijms20081916","volume":"20","author":"ML Sprouse","year":"2019","unstructured":"Sprouse ML, Welte T, Boral D, Liu HN, Yin W, Vishnoi M, et al. PMN-MDSCs enhance CTC metastatic properties through reciprocal interactions via ROS\/Notch\/Nodal signaling. Int J Mol Sci. 2019;20(8):1916. https:\/\/doi.org\/10.3390\/ijms20081916.","journal-title":"IJMS"},{"issue":"5","key":"1856_CR122","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","volume":"158","author":"N Aceto","year":"2014","unstructured":"Aceto N, Bardia A, Miyamoto DT, Donaldson M, Wittner B, Spencer J, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110\u201322. https:\/\/doi.org\/10.1016\/j.cell.2014.07.013.","journal-title":"Cell"},{"issue":"9826","key":"1856_CR123","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","volume":"379","author":"PM Rothwell","year":"2012","unstructured":"Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591\u2013601. https:\/\/doi.org\/10.1016\/S0140-6736(12)60209-8.","journal-title":"Lancet"},{"issue":"3","key":"1856_CR124","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrclinonc.2016.144","volume":"14","author":"M Mohme","year":"2017","unstructured":"Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells \u2014 mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2017;14(3):155\u201367. https:\/\/doi.org\/10.1038\/nrclinonc.2016.144.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1856_CR125","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrc3793","volume":"14","author":"MS Sosa","year":"2014","unstructured":"Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14(9):611\u201322. https:\/\/doi.org\/10.1038\/nrc3793.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1856_CR126","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ccell.2025.02.011","volume":"43","author":"M Yang","year":"2025","unstructured":"Yang M, Zhao Y, Li C, Weng X, Li Z, Guo W, et al. Multimodal integration of liquid biopsy and radiology for the noninvasive diagnosis of gallbladder cancer and benign disorders. Cancer Cell. 2025;43(3):398\u2013412.e4. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.011.","journal-title":"Cancer Cell"},{"issue":"8066","key":"1856_CR127","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41586-025-08927-x","volume":"642","author":"G Pei","year":"2025","unstructured":"Pei G, Min J, Rajapakshe KI, Branchi V, Liu Y, Selvanesan BC, et al. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Nature. 2025;642(8066):212\u201321. https:\/\/doi.org\/10.1038\/s41586-025-08927-x.","journal-title":"Nature"},{"issue":"1","key":"1856_CR128","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12935-025-03966-w","volume":"25","author":"W Pan","year":"2025","unstructured":"Pan W, Gao X, Zhang X, Li Y, Zhao Q, Wang D, et al. Exosomes promote pre-metastatic niche formation in lung cancer. Cancer Cell Int. 2025;25(1):379. https:\/\/doi.org\/10.1186\/s12935-025-03966-w.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1856_CR129","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41467-025-56878-8","volume":"16","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Yu H, Li J, Qian J, Li M, Zhang X, et al. A glucose-enriched lung pre-metastatic niche triggered by matrix stiffness-tuned exosomal miRnas in hepatocellular carcinoma. Nat Commun. 2025;16(1):1736. https:\/\/doi.org\/10.1038\/s41467-025-56878-8.","journal-title":"Nat Commun"},{"issue":"12","key":"1856_CR130","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1136\/gutjnl-2025-334851","volume":"74","author":"J Cao","year":"2025","unstructured":"Cao J, Qin S, Li B, Zhang Z, Miao P, Yan H, et al. Extracellular vesicle-induced lipid dysregulation drives liver premetastatic niche formation in colorectal cancer. Gut. 2025;74(12):2012\u201323. https:\/\/doi.org\/10.1136\/gutjnl-2025-334851.","journal-title":"Gut"},{"key":"1856_CR131","doi-asserted-by":"publisher","unstructured":"Vrynas A, Bazban-Shotorbani S, Arfan S, Satia K, Cunningham B, Sagindykova G, et al. Circulating tumor cells shed shearosome extracellular vesicles in capillary bifurcations that activate endothelial and immune cells. Adv Sci (Weinh). 2025;12(31):e06339. https:\/\/doi.org\/10.1002\/advs.202506339.","DOI":"10.1002\/advs.202506339"},{"key":"1856_CR132","doi-asserted-by":"publisher","first-page":"218102","DOI":"10.1016\/j.canlet.2025.218102","volume":"635","author":"Z Guo","year":"2025","unstructured":"Guo Z, Liu J, Zhang M, Zheng W, Zhuang J, Sun C. Biomechanical networks of the pre-metastatic niche: decoding biophysical determinants of tumor metastatic organotropism. Cancer Lett. 2025;635:218102. https:\/\/doi.org\/10.1016\/j.canlet.2025.218102.","journal-title":"Cancer Lett"},{"key":"1856_CR133","doi-asserted-by":"publisher","unstructured":"Wu L, Wu G, Wu D, Hu W, Du Q, Lu Q, et al. Stiffness-tunable hydrogel microfluidic chip reveals the role of stiffness in cholangiocarcinoma invasion and pre-metastatic niche formation. Adv Healthcare Mater. 2026;15(9):e03515. https:\/\/doi.org\/10.1002\/adhm.202503515.","DOI":"10.1002\/adhm.202503515"},{"issue":"1","key":"1856_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01937-7","volume":"9","author":"Y Wang","year":"2024","unstructured":"Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q, et al. Pre-metastatic niche: formation, characteristics and therapeutic implication. Sig Transduct Target Ther. 2024;9(1):1\u201331. https:\/\/doi.org\/10.1038\/s41392-024-01937-7.","journal-title":"Sig Transduct Target Ther"},{"issue":"7","key":"1856_CR135","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1609","volume":"13","author":"S Nagaraj","year":"2007","unstructured":"Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7):828\u201335. https:\/\/doi.org\/10.1038\/nm1609.","journal-title":"Nat Med"},{"issue":"5","key":"1856_CR136","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00109-015-1376-x","volume":"94","author":"Y Liu","year":"2016","unstructured":"Liu Y, Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med (Berl). 2016;94(5):509\u201322. https:\/\/doi.org\/10.1007\/s00109-015-1376-x.","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"1856_CR137","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/0008-5472.CAN-19-2013","volume":"80","author":"B Jing","year":"2020","unstructured":"Jing B, Wang T, Sun B, Xu J, Xu D, Liao Y, et al. IL6\/STAT3 signaling orchestrates premetastatic niche formation and immunosuppressive traits in lung. Cancer Res. 2020;80(4):784\u201397. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2013.","journal-title":"Cancer Res"},{"key":"1856_CR138","doi-asserted-by":"publisher","unstructured":"Jiang Y, Long G, Huang X, Wang W, Cheng B, Pan W. Single-cell transcriptomic analysis reveals dynamic changes in the liver microenvironment during colorectal cancer metastatic progression. J Transl Med. 2025;23(1). https:\/\/doi.org\/10.1186\/s12967-025-06351-3.","DOI":"10.1186\/s12967-025-06351-3"},{"issue":"1","key":"1856_CR139","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccell.2024.12.004","volume":"43","author":"W Lee","year":"2025","unstructured":"Lee W, Ko SY, Akasaka H, Weigert M, Lengyel E, Naora H. Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. Cancer Cell. 2025;43(1):69\u201385.e11. https:\/\/doi.org\/10.1016\/j.ccell.2024.12.004.","journal-title":"Cancer Cell"},{"issue":"6","key":"1856_CR140","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.3892\/or.2014.3516","volume":"32","author":"S Liu","year":"2014","unstructured":"Liu S, Jiang M, Zhao Q, Li S, Peng Y, Zhang P, et al. Vascular endothelial growth factor plays a critical role in the formation of the pre-metastatic niche via prostaglandin E2. Oncol Rep. 2014;32(6):2477\u201384. https:\/\/doi.org\/10.3892\/or.2014.3516.","journal-title":"Oncol Rep"},{"issue":"1","key":"1856_CR141","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1038\/ncomms5715","volume":"5","author":"E Lee","year":"2014","unstructured":"Lee E, Fertig EJ, Jin K, Sukumar S, Pandey NB, Popel AS. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nat Commun. 2014;5(1):4715. https:\/\/doi.org\/10.1038\/ncomms5715.","journal-title":"Nat Commun"},{"issue":"12","key":"1856_CR142","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41419-024-07311-3","volume":"15","author":"T Gao","year":"2024","unstructured":"Gao T, Li J, Cheng T, Wang X, Wang M, Xu Z, et al. Ovarian cancer-derived TGF-\u03b21 induces cancer-associated adipocytes formation by activating SMAD3\/TRIB3 pathway to establish pre-metastatic niche. Cell Death Dis. 2024;15(12):930. https:\/\/doi.org\/10.1038\/s41419-024-07311-3.","journal-title":"Cell Death Dis"},{"issue":"6","key":"1856_CR143","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ncb3169","volume":"17","author":"B Costa-Silva","year":"2015","unstructured":"Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur B, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816\u201326. https:\/\/doi.org\/10.1038\/ncb3169.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1856_CR144","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccr.2008.11.012","volume":"15","author":"JT Erler","year":"2009","unstructured":"Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009;15(1):35\u201344. https:\/\/doi.org\/10.1016\/j.ccr.2008.11.012.","journal-title":"Cancer Cell"},{"issue":"6","key":"1856_CR145","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1158\/0008-5472.CAN-15-0204","volume":"76","author":"AJ Giles","year":"2016","unstructured":"Giles AJ, Reid CM, Evans JD, Murgai M, Vicioso Y, Highfill SL, et al. Activation of hematopoietic Stem\/Progenitor cells promotes immunosuppression within the pre\u2013metastatic niche. Cancer Res. 2016;76(6):1335\u201347. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0204.","journal-title":"Cancer Res"},{"issue":"1","key":"1856_CR146","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.molonc.2016.09.009","volume":"11","author":"RR Gomis","year":"2017","unstructured":"Gomis RR, Gawrzak S. Tumor cell dormancy. Mol Oncol. 2017;11(1):62\u201378. https:\/\/doi.org\/10.1016\/j.molonc.2016.09.009.","journal-title":"Mol Oncol"},{"issue":"1","key":"1856_CR147","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.urolonc.2003.12.012","volume":"22","author":"JA Aguirre-Ghiso","year":"2004","unstructured":"Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Urologic Oncol: Semin Original Investigations. 2004;22(1):82\u20131695. https:\/\/doi.org\/10.1016\/j.urolonc.2003.12.012.","journal-title":"Urologic Oncol: Semin Original Investigations"},{"issue":"8","key":"1856_CR148","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc3556","volume":"13","author":"S Sadasivam","year":"2013","unstructured":"Sadasivam S, DeCaprio JA. The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer. 2013;13(8):585\u201395. https:\/\/doi.org\/10.1038\/nrc3556.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1856_CR149","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1038\/ncomms7170","volume":"6","author":"MS Sosa","year":"2015","unstructured":"Sosa MS, Parikh F, Maia AG, Estrada Y, Bosch A, Bragado P, et al. NR2F1 controls tumour cell dormancy via SOX9- and RAR\u03b2-driven quiescence programmes. Nat Commun. 2015;6(1):6170. https:\/\/doi.org\/10.1038\/ncomms7170.","journal-title":"Nat Commun"},{"key":"1856_CR150","doi-asserted-by":"publisher","first-page":"627023","DOI":"10.3389\/fonc.2021.627023","volume":"11","author":"Y Akkoc","year":"2021","unstructured":"Akkoc Y, Peker N, Akcay A, Gozuacik D. Autophagy and cancer dormancy. Front Oncol. 2021;11:627023. https:\/\/doi.org\/10.3389\/fonc.2021.627023.","journal-title":"Front Oncol"},{"key":"1856_CR151","doi-asserted-by":"publisher","first-page":"103480","DOI":"10.1016\/j.redox.2024.103480","volume":"80","author":"B Puente-Cobacho","year":"2025","unstructured":"Puente-Cobacho B, Esteo C, Altea-Manzano P, Garcia-Perez JL, Quiles JL, Sanchez-Rovira P, et al. De Novo lipogenesis protects dormant breast cancer cells from ferroptosis and promotes metastasis. Redox Biol. 2025;80:103480. https:\/\/doi.org\/10.1016\/j.redox.2024.103480.","journal-title":"Redox Biol"},{"issue":"3","key":"1856_CR152","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/0008-5472.CAN-08-2590","volume":"69","author":"N Almog","year":"2009","unstructured":"Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 2009;69(3):836\u201344. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2590.","journal-title":"Cancer Res"},{"issue":"7","key":"1856_CR153","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/ncb2767","volume":"15","author":"CM Ghajar","year":"2013","unstructured":"Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013;15(7):807\u201317. https:\/\/doi.org\/10.1038\/ncb2767.","journal-title":"Nat Cell Biol"},{"issue":"7171","key":"1856_CR154","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nature06309","volume":"450","author":"CM Koebel","year":"2007","unstructured":"Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450(7171):903\u201307. https:\/\/doi.org\/10.1038\/nature06309.","journal-title":"Nature"},{"issue":"7437","key":"1856_CR155","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature11824","volume":"494","author":"H Braum\u00fcller","year":"2013","unstructured":"Braum\u00fcller H, Wieder T, Brenner E, A\u00dfmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494(7437):361\u201365. https:\/\/doi.org\/10.1038\/nature11824.","journal-title":"Nature"},{"issue":"11","key":"1856_CR156","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/ncb2861","volume":"15","author":"P Bragado","year":"2013","unstructured":"Bragado P, Estrada Y, Parikh F, Krause S, Capobianco C, Farina HG, et al. TGF-\u03b22 dictates disseminated tumour cell fate in target organs through TGF-\u03b2-RIII and p38\u03b1\/\u03b2 signalling. Nat Cell Biol. 2013;15(11):1351\u201361. https:\/\/doi.org\/10.1038\/ncb2861.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"1856_CR157","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/hep.24108","volume":"53","author":"J Schrader","year":"2011","unstructured":"Schrader J, Gordon-Walker TT, Aucott RL, van Deemter M, Quaas A, Walsh S, et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology. 2011;53(4):1192\u2013205. https:\/\/doi.org\/10.1002\/hep.24108.","journal-title":"Hepatology"},{"key":"1856_CR158","doi-asserted-by":"publisher","first-page":"217468","DOI":"10.1016\/j.canlet.2025.217468","volume":"612","author":"O Gilon-Zaltsman","year":"2025","unstructured":"Gilon-Zaltsman O, Weidenfeld-Barenboim K, Samara H, Feuermann Y, Michaeli-Ashkenasi S, Schif-Zuck S, et al. Targeting dormant disseminated tumor cells and their permissive niche by pro-resolving mediators derived from resolution-phase macrophages. Cancer Lett. 2025;612:217468. https:\/\/doi.org\/10.1016\/j.canlet.2025.217468.","journal-title":"Cancer Lett"},{"issue":"6","key":"1856_CR159","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccr.2011.11.002","volume":"20","author":"X Lu","year":"2011","unstructured":"Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging \u03b14\u03b21-positive osteoclast progenitors. Cancer Cell. 2011;20(6):701\u201314. https:\/\/doi.org\/10.1016\/j.ccr.2011.11.002.","journal-title":"Cancer Cell"},{"issue":"1","key":"1856_CR160","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1038\/s41467-025-66376-6","volume":"16","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wang M, Dong B, Wang Y, Ding Z, Shen S. Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside. Nat Commun. 2025;16(1):10048. https:\/\/doi.org\/10.1038\/s41467-025-66376-6.","journal-title":"Nat Commun"},{"issue":"7","key":"1856_CR161","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Liquid biopsy and minimal residual disease \u2014 latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409\u201324. https:\/\/doi.org\/10.1038\/s41571-019-0187-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"1856_CR162","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s43018-020-0088-5","volume":"1","author":"E Risson","year":"2020","unstructured":"Risson E, Nobre AR, Maguer-Satta V, Aguirre-Ghiso JA. The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer. 2020;1(7):672\u201380. https:\/\/doi.org\/10.1038\/s43018-020-0088-5.","journal-title":"Nat Cancer"},{"issue":"3421","key":"1856_CR163","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"133","author":"S Paget","year":"1889","unstructured":"Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;133(3421):571\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(00)49915-0.","journal-title":"Lancet"},{"issue":"5","key":"1856_CR164","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc.2017.6","volume":"17","author":"H Peinado","year":"2017","unstructured":"Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017;17(5):302\u201317. https:\/\/doi.org\/10.1038\/nrc.2017.6.","journal-title":"Nat Rev Cancer"},{"issue":"7355","key":"1856_CR165","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"B Qian","year":"2011","unstructured":"Qian B, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222\u201325. https:\/\/doi.org\/10.1038\/nature10138.","journal-title":"Nature"},{"issue":"14","key":"1856_CR166","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1158\/1078-0432.CCR-13-1059","volume":"20","author":"TR Cox","year":"2014","unstructured":"Cox TR, Erler JT. Molecular pathways: connecting fibrosis and solid tumor metastasis. Clin Cancer Res. 2014;20(14):3637\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1059.","journal-title":"Clin Cancer Res"},{"issue":"7355","key":"1856_CR167","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","volume":"475","author":"A Facciabene","year":"2011","unstructured":"Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang L-P, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature. 2011;475(7355):226\u201330. https:\/\/doi.org\/10.1038\/nature10169.","journal-title":"Nature"},{"issue":"24","key":"1856_CR168","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.1158\/1078-0432.CCR-16-0460","volume":"22","author":"P Brodt","year":"2016","unstructured":"Brodt P. Role of the microenvironment in liver metastasis: from pre- to prometastatic niches. Clin Cancer Res. 2016;22(24):5971\u201382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0460.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1856_CR169","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","volume":"12","author":"S Affo","year":"2017","unstructured":"Affo S, Yu LX, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol Mech Dis. 2017;12(1):153\u201386. https:\/\/doi.org\/10.1146\/annurev-pathol-052016-100322.","journal-title":"Annu. Rev. Pathol. Mech. Dis"},{"issue":"11\u201312","key":"1856_CR170","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s12272-025-01581-x","volume":"48","author":"H Lee","year":"2025","unstructured":"Lee H, Kwon YJ, Chun YJ. Exploring the roles of cytochrome P450 enzymes and their inhibitors in cancers and non-neoplastic human diseases. Arch Pharm Res. 2025;48(11\u201312):1224\u201352. https:\/\/doi.org\/10.1007\/s12272-025-01581-x.","journal-title":"Arch Pharm Res"},{"issue":"5","key":"1856_CR171","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017;5(5):417\u201324. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0325.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1856_CR172","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","volume":"6","author":"RE Coleman","year":"2020","unstructured":"Coleman RE, Croucher PI, Padhani AR, Cl\u00e9zardin P, Chow E, Fallon M, et al. Bone metastases. Nat Rev Dis Primers. 2020;6(1):83. https:\/\/doi.org\/10.1038\/s41572-020-00216-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1856_CR173","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","volume":"49","author":"RGG Russell","year":"2011","unstructured":"Russell RGG. Bisphosphonates: the first 40years. Bone. 2011;49(1):2\u201319. https:\/\/doi.org\/10.1016\/j.bone.2011.04.022.","journal-title":"Bone"},{"issue":"16","key":"1856_CR174","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (Oxford, Engl: 1990). 2012;48(16):3082\u201392. https:\/\/doi.org\/10.1016\/j.ejca.2012.08.002.","journal-title":"Eur J Cancer (Oxford, Engl: 1990)"},{"issue":"1","key":"1856_CR175","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","volume":"5","author":"AS Achrol","year":"2019","unstructured":"Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, et al. Brain metastases. Nat Rev Dis Primers. 2019;5(1):5. https:\/\/doi.org\/10.1038\/s41572-018-0055-y.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"1856_CR176","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/path.4281","volume":"231","author":"P Sandoval","year":"2013","unstructured":"Sandoval P, Jim\u00e9nez-Heffernan JA, Rynne-Vidal \u00c1, P\u00e9rez-Lozano ML, Gilsanz \u00c1, Ruiz-Carpio V, et al. Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis. J Pathol. 2013;231(4):517\u201331. https:\/\/doi.org\/10.1002\/path.4281.","journal-title":"The J Pathol"},{"issue":"4","key":"1856_CR177","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DSP, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13(4):273\u201382. https:\/\/doi.org\/10.1038\/nrc3432.","journal-title":"Nat Rev Cancer"},{"key":"1856_CR178","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.semcancer.2026.02.001","volume":"120","author":"TGP Gr\u00fcnewald","year":"2026","unstructured":"Gr\u00fcnewald TGP, Oehme I, Wagner J, Fr\u00f6hling S. Intratumor heterogeneity and clonal evolution in sarcomas: molecular, cellular, and functional drivers of therapy resistance. Semin Cancer Biol. 2026;120:31\u201347. https:\/\/doi.org\/10.1016\/j.semcancer.2026.02.001.","journal-title":"Semin Cancer Biol"},{"key":"1856_CR179","doi-asserted-by":"publisher","unstructured":"Venkatesan S, Swanton C, Taylor BS, Costello JF. Treatment-induced mutagenesis and selective pressures sculpt cancer evolution. Cold Spring Harb Perspect Med. 2017;7(8):a026617. https:\/\/doi.org\/10.1101\/cshperspect.a026617.","DOI":"10.1101\/cshperspect.a026617"},{"key":"1856_CR180","doi-asserted-by":"publisher","first-page":"101380","DOI":"10.1016\/j.drup.2026.101380","volume":"86","author":"C Jin","year":"2026","unstructured":"Jin C, Li W, Liu B, Cao L-Q, Stefan SM, Yuan L, et al. Emerging trends and converging evidence in tumor evolution: a comprehensive review. Drug Resist Updates. 2026;86:101380. https:\/\/doi.org\/10.1016\/j.drup.2026.101380.","journal-title":"Drug Resist Updates"},{"issue":"6","key":"1856_CR181","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients. Nat Med. 2017;23(6):703\u201313. https:\/\/doi.org\/10.1038\/nm.4333.","journal-title":"Nat Med"},{"issue":"9","key":"1856_CR182","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.annonc.2025.04.004","volume":"36","author":"L Belcaid","year":"2025","unstructured":"Belcaid L, H\u00f8jgaard M, Tuxen I, Spanggaard I, Lassen U, Robinson L, et al. Copenhagen prospective personalized oncology (CoPPO)\u2014impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting. Ann Oncol. 2025;36(9):1078\u201387. https:\/\/doi.org\/10.1016\/j.annonc.2025.04.004.","journal-title":"Ann Oncol"},{"issue":"3","key":"1856_CR183","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41591-025-04175-8","volume":"32","author":"H Lee","year":"2026","unstructured":"Lee H, Ahn S, Gonzales GA, Leblay N, Barakat E, Greening D, et al. Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma. Nat Med. 2026;32(3):964\u201377. https:\/\/doi.org\/10.1038\/s41591-025-04175-8.","journal-title":"Nat Med"},{"issue":"4","key":"1856_CR184","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613\u201328. https:\/\/doi.org\/10.1016\/j.cell.2017.01.018.","journal-title":"Cell"},{"issue":"1","key":"1856_CR185","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12943-025-02323-9","volume":"24","author":"S Liu","year":"2025","unstructured":"Liu S, Jiang A, Tang F, Duan M, Li B. Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment. Mol Cancer. 2025;24(1):150. https:\/\/doi.org\/10.1186\/s12943-025-02323-9.","journal-title":"Mol Cancer"},{"issue":"8","key":"1856_CR186","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, J\u00e4nne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non\u2013small-Cell lung cancer to Gefitinib. N Engl J Med. 2005;352(8):786\u201392. https:\/\/doi.org\/10.1056\/NEJMoa044238.","journal-title":"N Engl J Med"},{"issue":"6","key":"1856_CR187","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560\u201362. https:\/\/doi.org\/10.1038\/nm.3854.","journal-title":"Nat Med"},{"issue":"2","key":"1856_CR188","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord CJ, Ashworth A. Brcaness revisited. Nat Rev Cancer. 2016;16(2):110\u201320. https:\/\/doi.org\/10.1038\/nrc.2015.21.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1856_CR189","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1604958.","journal-title":"N Engl J Med"},{"issue":"8","key":"1856_CR190","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrg3922","volume":"16","author":"D Hughes","year":"2015","unstructured":"Hughes D, Andersson DI. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet. 2015;16(8):459\u201371. https:\/\/doi.org\/10.1038\/nrg3922.","journal-title":"Nat Rev Genet"},{"issue":"1\u20132","key":"1856_CR191","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.drup.2012.03.002","volume":"15","author":"KM Pluchino","year":"2012","unstructured":"Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updates. 2012;15(1\u20132):98\u2013105. https:\/\/doi.org\/10.1016\/j.drup.2012.03.002.","journal-title":"Drug Resist Updates"},{"issue":"1","key":"1856_CR192","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12935-025-03734-w","volume":"25","author":"YC Fu","year":"2025","unstructured":"Fu YC, Liang SB, Luo M, Wang XP. Intratumoral heterogeneity and drug resistance in cancer. Cancer Cell Int. 2025;25(1):103. https:\/\/doi.org\/10.1186\/s12935-025-03734-w.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1856_CR193","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41422-024-01030-2","volume":"35","author":"S Nouruzi","year":"2025","unstructured":"Nouruzi S, Zoubeidi A. LKB1 inactivation unleashes prostate cancer lineage plasticity. Cell Res. 2025;35(1):5\u20136. https:\/\/doi.org\/10.1038\/s41422-024-01030-2.","journal-title":"Cell Res"},{"key":"1856_CR194","doi-asserted-by":"publisher","unstructured":"Li L, Ha T, Feng JX, et al. Targeting the epigenome and the integrated stress response to normalize colorectal cancer subclonal plasticity and progression. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-026-08720-2. Published online April 10, 2026.","DOI":"10.1038\/s41419-026-08720-2"},{"issue":"11","key":"1856_CR195","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41422-025-01180-x","volume":"35","author":"X Li","year":"2025","unstructured":"Li X, Gardner EE, Molina-Pinelo S, Wilhelm C, Mu P, Quintanal-Villalonga \u00c1. Lineage plasticity and histological transformation: tumor histology as a spectrum. Cell Res. 2025;35(11):803\u201323. https:\/\/doi.org\/10.1038\/s41422-025-01180-x.","journal-title":"Cell Res"},{"issue":"3","key":"1856_CR196","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298\u2013305. https:\/\/doi.org\/10.1038\/nm.4045.","journal-title":"Nat Med"},{"issue":"10","key":"1856_CR197","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611\u201329. https:\/\/doi.org\/10.1038\/nrclinonc.2017.44.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1856_CR198","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69\u201380. https:\/\/doi.org\/10.1016\/j.cell.2010.02.027.","journal-title":"Cell"},{"issue":"4","key":"1856_CR199","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","volume":"174","author":"F Rambow","year":"2018","unstructured":"Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, et al. Toward minimal residual disease-directed therapy in melanoma. Cell. 2018;174(4):843\u201355.e19. https:\/\/doi.org\/10.1016\/j.cell.2018.06.025.","journal-title":"Cell"},{"issue":"39","key":"1856_CR200","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1038\/s41388-025-03560-4","volume":"44","author":"H Panda","year":"2025","unstructured":"Panda H, Rowland NG, Krall CM, Bowman BM, Major MB, Zolkind P. NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting. Oncogene. 2025;44(39):3641\u201351. https:\/\/doi.org\/10.1038\/s41388-025-03560-4.","journal-title":"Oncogene"},{"issue":"1","key":"1856_CR201","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/s41467-018-04070-6","volume":"9","author":"L Vera-Ramirez","year":"2018","unstructured":"Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW, Green JE. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat Commun. 2018;9(1):1944. https:\/\/doi.org\/10.1038\/s41467-018-04070-6.","journal-title":"Nat Commun"},{"issue":"1","key":"1856_CR202","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41467-022-29018-9","volume":"13","author":"M Wu","year":"2022","unstructured":"Wu M, Zhang X, Zhang W, Chiou YS, Qian W, Liu X, et al. Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis. Nat Commun. 2022;13(1):1371. https:\/\/doi.org\/10.1038\/s41467-022-29018-9.","journal-title":"Nat Commun"},{"key":"1856_CR203","doi-asserted-by":"publisher","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473. https:\/\/doi.org\/10.1126\/science.aaw5473.","DOI":"10.1126\/science.aaw5473"},{"issue":"7617","key":"1856_CR204","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature19084","volume":"536","author":"CM Sousa","year":"2016","unstructured":"Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 2016;536(7617):479\u201383. https:\/\/doi.org\/10.1038\/nature19084.","journal-title":"Nature"},{"issue":"7635","key":"1856_CR205","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nature20791","volume":"541","author":"G Pascual","year":"2017","unstructured":"Pascual G, Avgustinova A, Mejetta S, Mart\u00edn M, Castellanos A, Attolini CS-O, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2017;541(7635):41\u201345. https:\/\/doi.org\/10.1038\/nature20791.","journal-title":"Nature"},{"issue":"7679","key":"1856_CR206","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247\u201350. https:\/\/doi.org\/10.1038\/nature24297.","journal-title":"Nature"},{"issue":"7664","key":"1856_CR207","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547(7664):453\u201357. https:\/\/doi.org\/10.1038\/nature23007.","journal-title":"Nature"},{"issue":"12","key":"1856_CR208","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775\u201390. https:\/\/doi.org\/10.1038\/s41571-022-00689-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1856_CR209","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41423-019-0224-2","volume":"16","author":"G Habif","year":"2019","unstructured":"Habif G, Crinier A, Andr\u00e9 P, Vivier E, Narni-Mancinelli E. Targeting natural killer cells in solid tumors. Cell Mol Immunol. 2019;16(5):415\u201322. https:\/\/doi.org\/10.1038\/s41423-019-0224-2.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"1856_CR210","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","volume":"35","author":"W Liao","year":"2019","unstructured":"Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell. 2019;35(4):559\u201372.e7. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.008.","journal-title":"Cancer Cell"},{"issue":"1","key":"1856_CR211","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Exp Clin Cancer Res. 2025;44(1):145. https:\/\/doi.org\/10.1186\/s13046-025-03377-9.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7791","key":"1856_CR212","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549\u201355. https:\/\/doi.org\/10.1038\/s41586-019-1922-8.","journal-title":"Nature"},{"issue":"6316","key":"1856_CR213","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","volume":"354","author":"KE Pauken","year":"2016","unstructured":"Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 2016;354(6316):1160\u201365. https:\/\/doi.org\/10.1126\/science.aaf2807.","journal-title":"Science"},{"issue":"11","key":"1856_CR214","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1002\/1878-0261.13173","volume":"16","author":"M Jary","year":"2022","unstructured":"Jary M, Liu WW, Yan D, Bai I, Muranyi A, Colle E, et al. Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study. Mol Oncol. 2022;16(11):2260\u201373. https:\/\/doi.org\/10.1002\/1878-0261.13173.","journal-title":"Mol Oncol"},{"issue":"6","key":"1856_CR215","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1007\/s13346-021-01036-y","volume":"11","author":"SW Chung","year":"2021","unstructured":"Chung SW, Xie Y, Suk JS. Overcoming physical stromal barriers to cancer immunotherapy. Drug Deliv Transl Res. 2021;11(6):2430\u201347. https:\/\/doi.org\/10.1007\/s13346-021-01036-y.","journal-title":"Drug Deliv. Transl. Res"},{"issue":"1","key":"1856_CR216","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","volume":"62","author":"MA Jacobetz","year":"2013","unstructured":"Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112\u201320. https:\/\/doi.org\/10.1136\/gutjnl-2012-302529.","journal-title":"Gut"},{"issue":"11","key":"1856_CR217","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo CA, Condamine T, Lu L, Cotter MJ, Youn J-I, Cheng P, et al. HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439\u201353. https:\/\/doi.org\/10.1084\/jem.20100587.","journal-title":"J Exp Med"},{"issue":"4","key":"1856_CR218","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","volume":"4","author":"T Stylianopoulos","year":"2018","unstructured":"Stylianopoulos T, Munn LL, Jain RK. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside. Trends Cancer. 2018;4(4):292\u2013319. https:\/\/doi.org\/10.1016\/j.trecan.2018.02.005.","journal-title":"Trends Cancer"},{"issue":"1","key":"1856_CR219","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1186\/1471-2407-13-554","volume":"13","author":"N Willumsen","year":"2013","unstructured":"Willumsen N, Bager CL, Leeming DJ, Smith V, Karsdal MA, Dornan D, et al. Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls. BMC Cancer. 2013;13(1):554. https:\/\/doi.org\/10.1186\/1471-2407-13-554.","journal-title":"BMC Cancer"},{"issue":"12","key":"1856_CR220","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.141.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1856_CR221","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s10637-012-9869-8","volume":"31","author":"KJ Pienta","year":"2013","unstructured":"Pienta KJ, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, Crabb SJ, et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs. 2013;31(3):760\u201368. https:\/\/doi.org\/10.1007\/s10637-012-9869-8.","journal-title":"Invest New Drugs"},{"key":"1856_CR222","doi-asserted-by":"publisher","unstructured":"Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One. 2014;9(3):e90353. https:\/\/doi.org\/10.1371\/journal.pone.0090353.","DOI":"10.1371\/journal.pone.0090353"},{"issue":"13","key":"1856_CR223","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1002\/cam4.3117","volume":"9","author":"J Wen","year":"2020","unstructured":"Wen J, Ye F, Xie F, Liu D, Huang L, Fang C, et al. The role of surgical intervention for isolated breast cancer liver metastasis: results of case-control study with comparison to medical treatment. Cancer Med. 2020;9(13):4656\u201366. https:\/\/doi.org\/10.1002\/cam4.3117.","journal-title":"Cancer Med"},{"key":"1856_CR224","doi-asserted-by":"publisher","first-page":"116521","DOI":"10.1016\/j.intimp.2026.116521","volume":"177","author":"J Tan","year":"2026","unstructured":"Tan J, Zhang Y, Wang J, Xia Y, Pan Y, Zhao Q. Redefining surgical oncology: active immune microenvironment modulation beyond tumor resection. Int Immunopharmacol. 2026;177:116521. https:\/\/doi.org\/10.1016\/j.intimp.2026.116521.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"1856_CR225","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","volume":"77","author":"S Tohme","year":"2017","unstructured":"Tohme S, Simmons RL, Tsung A. Surgery for cancer: a trigger for metastases. Cancer Res. 2017;77(7):1548\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1536.","journal-title":"Cancer Res"},{"key":"1856_CR226","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semcancer.2019.08.019","volume":"60","author":"C D\u2019alterio","year":"2020","unstructured":"D\u2019alterio C, Scala S, Sozzi G, Roz L, Bertolini G. Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Semin Cancer Biol. 2020;60:351\u201361. https:\/\/doi.org\/10.1016\/j.semcancer.2019.08.019.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"1856_CR227","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41401-023-01093-8","volume":"44","author":"J-X Su","year":"2023","unstructured":"Su J-X, Li S-J, Zhou X-F, Zhang Z-J, Yan Y, Liu S-L, et al. Chemotherapy-induced metastasis: molecular mechanisms and clinical therapies. Acta Pharmacol Sin. 2023;44(9):1725\u201336. https:\/\/doi.org\/10.1038\/s41401-023-01093-8.","journal-title":"Acta Pharmacol Sin"},{"issue":"10295","key":"1856_CR228","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(21)00233-6","volume":"398","author":"RA Chandra","year":"2021","unstructured":"Chandra RA, Keane FK, Voncken FEM, Thomas CR. Contemporary radiotherapy: present and future. Lancet. 2021;398(10295):171\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00233-6.","journal-title":"Lancet"},{"issue":"4","key":"1856_CR229","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10585-017-9867-5","volume":"35","author":"BJ Blyth","year":"2018","unstructured":"Blyth BJ, Cole AJ, MacManus MP, Martin OA. Radiation therapy-induced metastasis: radiobiology and clinical implications. Clin Exp Metastasis. 2018;35(4):223\u201336. https:\/\/doi.org\/10.1007\/s10585-017-9867-5.","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"1856_CR230","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijrobp.2023.11.050","volume":"119","author":"KMB Bergerud","year":"2024","unstructured":"Bergerud KMB, Berkseth M, Pardoll DM, Ganguly S, Kleinberg LR, Lawrence J, et al. Radiation therapy and myeloid-derived suppressor cells: breaking down their cancerous partnership. Int J Radiat Oncol*Biol*Phys. 2024;119(1):42\u201355. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.11.050.","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"8072","key":"1856_CR231","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41586-025-08994-0","volume":"643","author":"A Piffk\u00f3","year":"2025","unstructured":"Piffk\u00f3 A, Yang K, Panda A, Heide J, Tesak K, Wen C, et al. Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025;643(8072):810\u201319. https:\/\/doi.org\/10.1038\/s41586-025-08994-0.","journal-title":"Nature"},{"issue":"7","key":"1856_CR232","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.3390\/jcm14072384","volume":"14","author":"SE Campos Ram\u00edrez","year":"2025","unstructured":"Campos Ram\u00edrez SE, Andr\u00e9s Garc\u00eda A, Blanco Abad C, Gomila Pons P, G\u00f3mez Mugarza P, Ruffini Egea SE, et al. Evaluation of the real-life efficacy and safety of the treatment with lutetium-177 dotatate for metastatic neuroendocrine tumors. J Clin Med. 2025;14(7):2384. https:\/\/doi.org\/10.3390\/jcm14072384.","journal-title":"JCM"},{"issue":"12","key":"1856_CR233","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"1856_CR234","doi-asserted-by":"publisher","unstructured":"Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015;7(313):313ra182. https:\/\/doi.org\/10.1126\/scitranslmed.aac7551.","DOI":"10.1126\/scitranslmed.aac7551"},{"issue":"11","key":"1856_CR235","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O\u2019leary","year":"2018","unstructured":"O\u2019leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390\u2013403. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0264.","journal-title":"Cancer Discov"},{"issue":"5","key":"1856_CR236","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1158\/0008-5472.CAN-13-2779","volume":"74","author":"MJ Sikora","year":"2014","unstructured":"Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, et al. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res. 2014;74(5):1463\u201374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2779.","journal-title":"Cancer Res"},{"issue":"11","key":"1856_CR237","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1315815.","journal-title":"N Engl J Med"},{"issue":"10","key":"1856_CR238","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.bbalip.2013.03.010","volume":"1831","author":"G Zadra","year":"2013","unstructured":"Zadra G, Photopoulos C, Loda M. The fat side of prostate cancer. Biochim et Biophys Acta (BBA) - Mol Cell Biol Lipids. 2013;1831(10):1518\u201332. https:\/\/doi.org\/10.1016\/j.bbalip.2013.03.010.","journal-title":"Biochim et Biophys Acta (BBA) - Mol Cell Biol Lipids"},{"key":"1856_CR239","doi-asserted-by":"publisher","unstructured":"Zhou X, Zeng L, Huang Z, Ruan Z, Yan H, Zou C, et al. Strategies beyond 3rd EGFR-TKI acquired resistance: opportunities and challenges. Cancer Med. 2025;14(9):e70921. https:\/\/doi.org\/10.1002\/cam4.70921.","DOI":"10.1002\/cam4.70921"},{"issue":"1","key":"1856_CR240","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","volume":"4","author":"H Shi","year":"2014","unstructured":"Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80\u201393. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0642.","journal-title":"Cancer Discov"},{"key":"1856_CR241","doi-asserted-by":"publisher","first-page":"105179","DOI":"10.1016\/j.critrevonc.2026.105179","volume":"221","author":"X Wen","year":"2026","unstructured":"Wen X, Wang W, Song J, Chen M, Xue W, Lin D, et al. Resistance mechanisms and post-trastuzumab deruxtecan (T-DXd) strategies in HER2+ and HER2-low breast cancer: from biology to clinical practice. Crit Rev Oncol\/Hematol. 2026;221:105179. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105179.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"21","key":"1856_CR242","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1158\/1078-0432.CCR-25-0206","volume":"31","author":"J Xue","year":"2025","unstructured":"Xue J, Ma Y, Zhao Y, Wang Y, Hong W, Huang Y, et al. Izalontamab (SI-B001), a novel EGFRxHER3 Bispecific antibody in patients with locally advanced or metastatic epithelial tumor: results from first-in-human phase I\/Ib study. Clin Cancer Res. 2025;31(21):4438\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0206.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1856_CR243","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","volume":"393","author":"JCH Yang","year":"2025","unstructured":"Yang JCH, Lu S, Hayashi H, Felip E, Spira AI, Girard N, et al. Overall survival with amivantamab\u2013lazertinib in EGFR -Mutated advanced NSCLC. N Engl J Med. 2025;393(17):1681\u201393. https:\/\/doi.org\/10.1056\/NEJMoa2503001.","journal-title":"N Engl J Med"},{"issue":"7","key":"1856_CR244","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y, et al. BL-B01D1, a first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024;25(7):901\u201311. https:\/\/doi.org\/10.1016\/S1470-2045(24)00159-1.","journal-title":"The Lancet Oncol"},{"issue":"4","key":"1856_CR245","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","volume":"26","author":"Z Li","year":"2025","unstructured":"Li Z, Wang Y, Sun Y, Wang L, Li X, Sun L, et al. Trastuzumab rezetecan, a HER2-directed antibody\u2013drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study. Lancet Oncol. 2025;26(4):437\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(25)00012-9.","journal-title":"The Lancet Oncol"},{"issue":"1","key":"1856_CR246","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-026-02612-9","volume":"11","author":"H Yao","year":"2026","unstructured":"Yao H, Yan M, Tong Z, Wu X, Yin Y, Ryu M-H, et al. SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial. Sig Transduct Target Ther. 2026;11(1):104. https:\/\/doi.org\/10.1038\/s41392-026-02612-9.","journal-title":"Sig Transduct Target Ther"},{"issue":"5","key":"1856_CR247","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JCO.24.00529","volume":"43","author":"N Turner","year":"2025","unstructured":"Turner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, et al. Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2\u2013positive advanced or metastatic breast cancer: an open-label, randomized, phase III trial (TULIP). J Clin Oncol: Off J Am Soc Clin Oncol. 2025;43(5):513\u201323. https:\/\/doi.org\/10.1200\/JCO.24.00529.","journal-title":"JCO"},{"issue":"1","key":"1856_CR248","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-025-02149-3","volume":"10","author":"X Hu","year":"2025","unstructured":"Hu X, Zhang Q, Wang L, Zhang J, Ouyang Q, Wang X, et al. ACE-breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer. Sig Transduct Target Ther. 2025;10(1):56. https:\/\/doi.org\/10.1038\/s41392-025-02149-3.","journal-title":"Sig Transduct Target Ther"},{"issue":"4","key":"1856_CR249","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara K, Van Cutsem E, G\u00fcm\u00fc\u015f M, Lonardi S, de la Fouchardi\u00e8re C, Coutzac C, et al. Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N Engl J Med. 2025;393(4):336\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2503119.","journal-title":"N Engl J Med"},{"key":"1856_CR250","doi-asserted-by":"publisher","unstructured":"J\u00e4nne PA, Planchard D, Goto K, Smit EF, de Langen AJ, Goto Y, et al. Trastuzumab deruxtecan for ERBB2 -mutant metastatic non\u2013small cell lung cancer with or without brain metastases. JAMA Netw Open. 2025;8(11):e2543107. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.43107.","DOI":"10.1001\/jamanetworkopen.2025.43107"},{"issue":"6","key":"1856_CR251","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJMoa2508668","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N Engl J Med. 2026;394(6):551\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2508668.","journal-title":"N Engl J Med"},{"issue":"24","key":"1856_CR252","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","volume":"30","author":"E Hamilton","year":"2024","unstructured":"Hamilton E, Galsky MD, Ochsenreither S, Del Conte G, Mart\u00edn M, De Miguel MJ, et al. Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase ib DS8201-a-U105 study. Clin Cancer Res. 2024;30(24):5548\u201358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1513.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1856_CR253","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim S-B, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. 2024;30(8):2208\u201315. https:\/\/doi.org\/10.1038\/s41591-024-03021-7.","journal-title":"Nat Med"},{"issue":"6","key":"1856_CR254","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","volume":"22","author":"S Siena","year":"2021","unstructured":"Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(21)00086-3.","journal-title":"The Lancet Oncol"},{"issue":"1","key":"1856_CR255","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","volume":"12","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor\u2013resistant, EGFR -Mutated non\u2013small cell lung cancer. Cancer Discov. 2022;12(1):74\u201389. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0715.","journal-title":"Cancer Discov"},{"issue":"10","key":"1856_CR256","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1038\/s41591-025-03885-3","volume":"31","author":"B Pistilli","year":"2025","unstructured":"Pistilli B, Mosele F, Corcos N, Pierotti L, Pradat Y, Le Bescond L, et al. Patritumab deruxtecan in HR+HER2\u2212 advanced breast cancer: a phase 2 trial. Nat Med. 2025;31(10):3492\u2013503. https:\/\/doi.org\/10.1038\/s41591-025-03885-3.","journal-title":"Nat Med"},{"issue":"6","key":"1856_CR257","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","volume":"31","author":"Y Yin","year":"2025","unstructured":"Yin Y, Fan Y, Ouyang Q, Song L, Wang X, Li W, et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2025;31(6):1969\u201375. https:\/\/doi.org\/10.1038\/s41591-025-03630-w.","journal-title":"Nat Med"},{"issue":"6","key":"1856_CR258","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1038\/s41591-025-03638-2","volume":"31","author":"S Zhao","year":"2025","unstructured":"Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, et al. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials. Nat Med. 2025;31(6):1976\u201386. https:\/\/doi.org\/10.1038\/s41591-025-03638-2.","journal-title":"Nat Med"},{"issue":"1","key":"1856_CR259","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-025-01705-2","volume":"18","author":"Q Ouyang","year":"2025","unstructured":"Ouyang Q, Rodon J, Liang Y, Wu X, Li Q, Song L, et al. Results of a phase 1\/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies. J Hematol Oncol. 2025;18(1):61. https:\/\/doi.org\/10.1186\/s13045-025-01705-2.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1856_CR260","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa2512071","volume":"394","author":"W Fang","year":"2026","unstructured":"Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W, et al. Sacituzumab tirumotecan in EGFR-TKI\u2013Resistant, EGFR -mutated advanced nsclc. N Engl J Med. 2026;394(1):13\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2512071.","journal-title":"N Engl J Med"},{"issue":"3","key":"1856_CR261","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.annonc.2025.11.013","volume":"37","author":"Y Zhu","year":"2026","unstructured":"Zhu Y, Jiang S, Shi Y, Wang S, Yuan F, Zhou F, et al. Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors. Ann Oncol. 2026;37(3):378\u201387. https:\/\/doi.org\/10.1016\/j.annonc.2025.11.013.","journal-title":"Ann Oncol"},{"issue":"12","key":"1856_CR262","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","volume":"30","author":"B Xu","year":"2024","unstructured":"Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, et al. Sacituzumab govitecan in HR+HER2\u2212 metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nat Med. 2024;30(12):3709\u201316. https:\/\/doi.org\/10.1038\/s41591-024-03269-z.","journal-title":"Nat Med"},{"issue":"19","key":"1856_CR263","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","volume":"393","author":"J Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med. 2025;393(19):1912\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2511734.","journal-title":"N Engl J Med"},{"issue":"15","key":"1856_CR264","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. JCO. 2024;42(15):1738\u201344. https:\/\/doi.org\/10.1200\/JCO.23.01409.","journal-title":"JCO"},{"issue":"2","key":"1856_CR265","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-022-06602-7","volume":"195","author":"J O\u2019shaughnessy","year":"2022","unstructured":"O\u2019shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, et al. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022;195(2):127\u201339. https:\/\/doi.org\/10.1007\/s10549-022-06602-7.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1856_CR266","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa2508959","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim S-B, Yam C, et al. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N Engl J Med. 2026;394(4):354\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2508959.","journal-title":"N Engl J Med"},{"issue":"3","key":"1856_CR267","doi-asserted-by":"publisher","first-page":"103509","DOI":"10.1016\/j.jtho.2025.10.016","volume":"21","author":"M Reck","year":"2026","unstructured":"Reck M, Patel JD, Gray JE, Reguart N, Cobo M, Pradera JF, et al. First-line sacituzumab govitecan plus pembrolizumab in metastatic NSCLC: PD-L1 TPS less than 50% and more than or equal to 50% cohorts of the EVOKE-02 study. J Thorac Oncol. 2026;21(3):103509. https:\/\/doi.org\/10.1016\/j.jtho.2025.10.016.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1856_CR268","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","volume":"36","author":"T Powles","year":"2025","unstructured":"Powles T, Tagawa S, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, et al. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. Ann Oncol. 2025;36(5):561\u201371. https:\/\/doi.org\/10.1016\/j.annonc.2025.01.011.","journal-title":"Ann Oncol"},{"issue":"9","key":"1856_CR269","doi-asserted-by":"publisher","first-page":"101707","DOI":"10.1016\/j.xcrm.2024.101707","volume":"5","author":"J Wang","year":"2024","unstructured":"Wang J, Tong Z, Tan Y, Shi Y, Wu Y, Zhou Q, et al. Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced\/metastatic solid tumors. Cell Rep Med. 2024;5(9):101707. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101707.","journal-title":"Cell Rep Med"},{"issue":"8","key":"1856_CR270","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.annonc.2025.04.009","volume":"36","author":"J Zhang","year":"2025","unstructured":"Zhang J, Liu R, Wang S, Feng Z, Yang H, Gao S, et al. Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation nectin-4 targeting antibody\u2013drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I\/II study. Ann Oncol. 2025;36(8):934\u201343. https:\/\/doi.org\/10.1016\/j.annonc.2025.04.009.","journal-title":"Ann Oncol"},{"issue":"15","key":"1856_CR271","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1200\/JCO-24-01989","volume":"43","author":"RR Aggarwal","year":"2025","unstructured":"Aggarwal RR, Vuky J, VanderWeele D, Rettig M, Heath EI, Quigley D, et al. Phase I, first-in-human study of FOR46 (FG-3246), an immune-modulating antibody-drug conjugate targeting CD46, in patients with metastatic castration-resistant prostate cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2025;43(15):1824\u201334. https:\/\/doi.org\/10.1200\/JCO-24-01989.","journal-title":"JCO"},{"issue":"5","key":"1856_CR272","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","volume":"22","author":"RL Coleman","year":"2021","unstructured":"Coleman RL, Lorusso D, Gennigens C, Gonz\u00e1lez-Mart\u00edn A, Randall L, Cibula D, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(5):609\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(21)00056-5.","journal-title":"The Lancet Oncol"},{"issue":"22","key":"1856_CR273","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/JCO-25-00678","volume":"43","author":"MN Stein","year":"2025","unstructured":"Stein MN, Vinceneux A, Robbrecht D, Doger B, Autio KA, Schweizer MT, et al. Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: a phase I study. J Clin Oncol: Off J Am Soc Clin Oncol. 2025;43(22):2515\u201326. https:\/\/doi.org\/10.1200\/JCO-25-00678.","journal-title":"JCO"},{"issue":"10","key":"1856_CR274","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00262-024-03790-7","volume":"73","author":"R Geva","year":"2024","unstructured":"Geva R, Vieito M, Ramon J, Perets R, Pedregal M, Corral E, et al. Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors. Cancer Immunol Immunother: CII. 2024;73(10):205. https:\/\/doi.org\/10.1007\/s00262-024-03790-7.","journal-title":"Cancer Immunol Immunother: CII"},{"issue":"6","key":"1856_CR275","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1470-2045(25)00140-8","volume":"26","author":"S Escriv\u00e1-de-Romani","year":"2025","unstructured":"Escriv\u00e1-de-Romani S, Cejalvo JM, Alba E, Friedmann J, Rodr\u00edguez-Lescure \u00c1, Savard M-F, et al. Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study. Lancet Oncol. 2025;26(6):745\u201358. https:\/\/doi.org\/10.1016\/S1470-2045(25)00140-8.","journal-title":"The Lancet Oncol"},{"issue":"2","key":"1856_CR276","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/1078-0432.CCR-24-4295","volume":"32","author":"KW Lee","year":"2026","unstructured":"Lee KW, Bai LY, Jung M, Ying J, Im Y-H, Oh D-Y, et al. Phase ib\/II study of zanidatamab in combination with tislelizumab and chemotherapy in first-line HER2-positive gastric\/gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2026;32(2):312\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-4295.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1856_CR277","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S1470-2045(25)00287-6","volume":"26","author":"E Elimova","year":"2025","unstructured":"Elimova E, Ajani J, Burris H, Denlinger CS, Iqbal S, Kang Y-K, et al. Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study. Lancet Oncol. 2025;26(7):847\u201359. https:\/\/doi.org\/10.1016\/S1470-2045(25)00287-6.","journal-title":"The Lancet Oncol"},{"issue":"1","key":"1856_CR278","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1038\/s41467-025-59279-z","volume":"16","author":"F Meric-Bernstam","year":"2025","unstructured":"Meric-Bernstam F, Rha SY, Hamilton E, Kang Y-K, Hanna DL, Iqbal S, et al. Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial. Nat Commun. 2025;16(1):4293. https:\/\/doi.org\/10.1038\/s41467-025-59279-z.","journal-title":"Nat Commun"},{"issue":"23","key":"1856_CR279","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-Instability\u2013High advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2017699.","journal-title":"N Engl J Med"},{"issue":"1","key":"1856_CR280","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","volume":"6","author":"S Maleki Vareki","year":"2018","unstructured":"Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):157. https:\/\/doi.org\/10.1186\/s40425-018-0479-7.","journal-title":"J. Immunother Cancer"},{"issue":"7693","key":"1856_CR281","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u201348. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"key":"1856_CR282","doi-asserted-by":"publisher","first-page":"1688699","DOI":"10.3389\/fimmu.2025.1688699","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, He J, Ding G, Tang Y, Wang Q. Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. Front Immunol. 2025;16:1688699. https:\/\/doi.org\/10.3389\/fimmu.2025.1688699.","journal-title":"Front. Immunol"},{"issue":"2","key":"1856_CR283","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon D, Schoenfeld AJ, Ye D, Fromm G, Rizvi H, Zhang X, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024;42(2):209\u201324.e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.12.013.","journal-title":"Cancer Cell"},{"key":"1856_CR284","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975. https:\/\/doi.org\/10.3389\/fimmu.2023.1167975.","journal-title":"Front. Immunol"},{"issue":"1","key":"1856_CR285","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407417.","journal-title":"N Engl J Med"},{"issue":"4","key":"1856_CR286","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","volume":"31","author":"L Shen","year":"2025","unstructured":"Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025;31(4):1163\u201370. https:\/\/doi.org\/10.1038\/s41591-024-03450-4.","journal-title":"Nat Med"},{"issue":"1","key":"1856_CR287","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41467-025-67375-3","volume":"17","author":"X Wu","year":"2025","unstructured":"Wu X, Wang J, Wang D, Li G, Zhang J, Chen H, et al. Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase ib\/II trial. Nat Commun. 2025;17(1):658. https:\/\/doi.org\/10.1038\/s41467-025-67375-3.","journal-title":"Nat Commun"},{"issue":"9","key":"1856_CR288","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41592-021-01203-6","volume":"18","author":"SM Lewis","year":"2021","unstructured":"Lewis SM, Asselin-Labat ML, Nguyen Q, Berthelet J, Tan X, Wimmer VC, et al. Spatial omics and multiplexed imaging to explore cancer biology. Nat Methods. 2021;18(9):997\u20131012. https:\/\/doi.org\/10.1038\/s41592-021-01203-6.","journal-title":"Nat Methods"},{"issue":"4","key":"1856_CR289","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41591-024-03486-6","volume":"31","author":"C Kurzeder","year":"2025","unstructured":"Kurzeder C, Nguyen-Str\u00e4uli BD, Krol I, Ring A, Castro-Giner F, N\u00fcesch M, et al. Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial. Nat Med. 2025;31(4):1120\u201324. https:\/\/doi.org\/10.1038\/s41591-024-03486-6.","journal-title":"Nat Med"},{"issue":"6","key":"1856_CR290","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.clbc.2013.08.006","volume":"13","author":"RP Roop","year":"2013","unstructured":"Roop RP, Naughton MJ, Van Poznak C, Schneider JG, Lammers PE, Pluard TJ, et al. A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer. Clin Breast Cancer. 2013;13(6):409\u201315. https:\/\/doi.org\/10.1016\/j.clbc.2013.08.006.","journal-title":"Clin Breast Cancer"},{"key":"1856_CR291","doi-asserted-by":"publisher","first-page":"123674","DOI":"10.1016\/j.biomaterials.2025.123674","volume":"326","author":"C Su","year":"2026","unstructured":"Su C, Song L, Wang X, Zhou Y, Chen M, Xu T, et al. Blockade of metastasis by targeting circulating tumor cells with platelet encapsuled oncolytic adenovirus. Biomaterials. 2026;326:123674. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123674.","journal-title":"Biomaterials"},{"issue":"2","key":"1856_CR292","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000542325","volume":"54","author":"S Ilic","year":"2024","unstructured":"Ilic S, Premuzic V. First-in-human rapid removal of circulating tumor cells in solid metastatic neoplasia by microbind affinity blood filter. Blood Purif. 2024;54(2):1\u20133. https:\/\/doi.org\/10.1159\/000542325.","journal-title":"Blood Purif"},{"issue":"3","key":"1856_CR293","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1634\/theoncologist.2017-0024","volume":"22","author":"AB Benson","year":"2017","unstructured":"Benson AB, Wainberg ZA, Hecht JR, Vyushkov D, Dong H, Bendell J, et al. A phase II randomized, double-blind, placebo-controlled study of simtuzumab or placebo in combination with gemcitabine for the first-line treatment of pancreatic adenocarcinoma. Oncologist. 2017;22(3):241\u2013e15. https:\/\/doi.org\/10.1634\/theoncologist.2017-0024.","journal-title":"Oncologist"},{"key":"1856_CR294","doi-asserted-by":"publisher","unstructured":"Khalil BD, Sanchez R, Rahman T, Rodriguez-Tirado C, Moritsch S, Martinez AR, et al. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2022;219(1):e20210836. https:\/\/doi.org\/10.1084\/jem.20210836.","DOI":"10.1084\/jem.20210836"},{"issue":"5","key":"1856_CR295","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","volume":"11","author":"R Aft","year":"2010","unstructured":"Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010;11(5):421\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(10)70054-1.","journal-title":"The Lancet Oncol"},{"issue":"9","key":"1856_CR296","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.ccell.2025.06.007","volume":"43","author":"D He","year":"2025","unstructured":"He D, Wu Q, Tian P, Liu Y, Jia Z, Li Z, et al. Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps. Cancer Cell. 2025;43(9):1622\u201336.e7. https:\/\/doi.org\/10.1016\/j.ccell.2025.06.007.","journal-title":"Cancer Cell"},{"issue":"10","key":"1856_CR297","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1038\/s41591-025-03877-3","volume":"31","author":"A DeMichele","year":"2025","unstructured":"DeMichele A, Clark AS, Shea E, Bayne LJ, Sterner CJ, Rohn K, et al. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial. Nat Med. 2025;31(10):3464\u201374. https:\/\/doi.org\/10.1038\/s41591-025-03877-3.","journal-title":"Nat Med"},{"key":"1856_CR298","doi-asserted-by":"publisher","unstructured":"Brazil L, Swampillai AL, Mak KM, Edwards D, Mesiri P, Clifton-Hadley L, et al. Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial. Neuro-Oncol Adv. 2020;2(1):vdaa046. https:\/\/doi.org\/10.1093\/noajnl\/vdaa046.","DOI":"10.1093\/noajnl\/vdaa046"},{"issue":"24","key":"1856_CR299","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1158\/1078-0432.CCR-23-1427","volume":"29","author":"V Calvo","year":"2023","unstructured":"Calvo V, Zheng W, Adam-Artigues A, Staschke KA, Huang X, Cheung JF, et al. A PERK-Specific inhibitor blocks metastatic progression by limiting integrated stress response\u2013dependent survival of quiescent cancer cells. Clin Cancer Res. 2023;29(24):5155\u201372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1427.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1856_CR300","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31(5):1509\u201318. https:\/\/doi.org\/10.1038\/s41591-025-03579-w.","journal-title":"Nat Med"},{"issue":"9","key":"1856_CR301","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMoa2514661","volume":"394","author":"S Loibl","year":"2026","unstructured":"Loibl S, Park YH, Shao Z, Huang C-S, Barrios C, Abraham J, et al. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med. 2026;394(9):845\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2514661.","journal-title":"N Engl J Med"},{"issue":"8056","key":"1856_CR302","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature. 2025;639(8056):1042\u201351. https:\/\/doi.org\/10.1038\/s41586-024-08508-4.","journal-title":"Nature"},{"issue":"4","key":"1856_CR303","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269\u201381. https:\/\/doi.org\/10.1038\/nri3191.","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"1856_CR304","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, Met \u00d6, Kessels R, Geukes Foppen MH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2210233.","journal-title":"N Engl J Med"},{"issue":"1","key":"1856_CR305","doi-asserted-by":"publisher","first-page":"2546402","DOI":"10.1080\/2162402X.2025.2546402","volume":"14","author":"M Hasanov","year":"2025","unstructured":"Hasanov M, Kiany S, Forget MA, Bassett R, Davies MA, Diab A, et al. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology. 2025;14(1):2546402. https:\/\/doi.org\/10.1080\/2162402X.2025.2546402.","journal-title":"Oncoimmunology"},{"key":"1856_CR306","doi-asserted-by":"publisher","unstructured":"Ferris RLM, Leidner RS, Chung CH, Jimeno A, Lee SM, Sukari A, et al. Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. J ImmunoTher Cancer. 2025;13(8):e011633. https:\/\/doi.org\/10.1136\/jitc-2025-011633.","DOI":"10.1136\/jitc-2025-011633"},{"issue":"6","key":"1856_CR307","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","volume":"18","author":"SS Chandran","year":"2017","unstructured":"Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017;18(6):792\u2013802. https:\/\/doi.org\/10.1016\/S1470-2045(17)30251-6.","journal-title":"The Lancet Oncol"},{"issue":"9","key":"1856_CR308","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/s41591-024-03109-0","volume":"30","author":"M Parkhurst","year":"2024","unstructured":"Parkhurst M, Goff SL, Lowery FJ, Beyer RK, Halas H, Robbins PF, et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. Nat Med. 2024;30(9):2586\u201395. https:\/\/doi.org\/10.1038\/s41591-024-03109-0.","journal-title":"Nat Med"},{"issue":"15","key":"1856_CR309","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1200\/JCO-24-01466","volume":"43","author":"SP D\u2019angelo","year":"2025","unstructured":"D\u2019angelo SP, Druta M, Van Tine BA, Liebner D, Schuetze SM, Tap WD, et al. Letetresgene autoleucel in advanced\/metastatic myxoid\/round cell liposarcoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2025;43(15):1777\u201388. https:\/\/doi.org\/10.1200\/JCO-24-01466.","journal-title":"JCO"},{"issue":"10494","key":"1856_CR310","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405(10494):2049\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(25)00860-8.","journal-title":"Lancet"},{"issue":"9","key":"1856_CR311","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1016\/j.ymthe.2025.05.026","volume":"33","author":"B Li","year":"2025","unstructured":"Li B, Zhu X, Ge J, Zhang H, Gao Y, Bao X, et al. Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8+ T cell activation in patients with advanced colorectal cancer. Mol TherMolecular Ther. 2025;33(9):4509\u201328. https:\/\/doi.org\/10.1016\/j.ymthe.2025.05.026.","journal-title":"Mol TherMolecular Ther"},{"issue":"11","key":"1856_CR312","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00262-025-04196-9","volume":"74","author":"D Wang","year":"2025","unstructured":"Wang D, Li B, Shen G, Zhang H, Gao Y, Du Z, et al. NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study. Immunother Cancer Immunol Immunother. 2025;74(11):341. https:\/\/doi.org\/10.1007\/s00262-025-04196-9.","journal-title":"Immunother Cancer Immunol Immunother"},{"issue":"1","key":"1856_CR313","doi-asserted-by":"publisher","first-page":"10743","DOI":"10.1038\/s41467-024-53220-6","volume":"15","author":"MN Stein","year":"2024","unstructured":"Stein MN, Dumbrava EE, Teply BA, Gergis US, Guiterrez ME, Reshef R, et al. PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024;15(1):10743. https:\/\/doi.org\/10.1038\/s41467-024-53220-6.","journal-title":"Nat Commun"},{"issue":"6","key":"1856_CR314","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","volume":"30","author":"TB Dorff","year":"2024","unstructured":"Dorff TB, Blanchard MS, Adkins LN, Luebbert L, Leggett N, Shishido SN, et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2024;30(6):1636\u201344. https:\/\/doi.org\/10.1038\/s41591-024-02979-8.","journal-title":"Nat Med"},{"issue":"11","key":"1856_CR315","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1001\/jamaoncol.2024.3891","volume":"10","author":"N Chen","year":"2024","unstructured":"Chen N, Pu C, Zhao L, Li W, Wang C, Zhu R, et al. Chimeric antigen receptor T cells targeting CD19 and GCC in metastatic colorectal cancer: a nonrandomized clinical trial. JAMA Oncol. 2024;10(11):1532\u201336. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3891.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1856_CR316","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","volume":"24","author":"Y Guo","year":"2018","unstructured":"Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q, et al. Phase I study of chimeric antigen receptor\u2013modified T cells in patients with EGFR-Positive advanced biliary tract cancers. Clin Cancer Res. 2018;24(6):1277\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0432.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1856_CR317","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","volume":"9","author":"K Feng","year":"2018","unstructured":"Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell. 2018;9(10):838\u201347. https:\/\/doi.org\/10.1007\/s13238-017-0440-4.","journal-title":"Protein Cell"},{"issue":"29","key":"1856_CR318","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","volume":"35","author":"YC Lu","year":"2017","unstructured":"Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, et al. Treatment of patients with metastatic cancer using a Major histocompatibility complex class II\u2013restricted T-Cell receptor targeting the cancer germline antigen MAGE-A3. J Clin Oncol: Off J Am Soc Clin Oncol. 2017;35(29):3322\u201329. https:\/\/doi.org\/10.1200\/JCO.2017.74.5463.","journal-title":"JCO"},{"issue":"16","key":"1856_CR319","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1215134.","journal-title":"N Engl J Med"},{"issue":"4","key":"1856_CR320","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s43018-026-01124-3","volume":"7","author":"Y Gao","year":"2026","unstructured":"Gao Y, Li J, Zhang H, Zhang Y, Qian S, Zhu X, et al. Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial. Nat Cancer. 2026;7(4):608\u201321. https:\/\/doi.org\/10.1038\/s43018-026-01124-3.","journal-title":"Nat Cancer"},{"issue":"7","key":"1856_CR321","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00262-023-03386-7","volume":"72","author":"YJ Yu","year":"2023","unstructured":"Yu YJ, Shan N, Li LY, Zhu Y-S, Lin L-M, Mao C-C, et al. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer. Cancer Immunol, Immunother: CII. 2023;72(7):2045\u201356. https:\/\/doi.org\/10.1007\/s00262-023-03386-7.","journal-title":"Cancer Immunol, Immunother: CII"},{"issue":"9","key":"1856_CR322","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","volume":"40","author":"MM Awad","year":"2022","unstructured":"Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell. 2022;40(9):1010\u201326.e11. https:\/\/doi.org\/10.1016\/j.ccell.2022.08.003.","journal-title":"Cancer Cell"},{"key":"1856_CR323","doi-asserted-by":"publisher","first-page":"572172","DOI":"10.3389\/fimmu.2020.572172","volume":"11","author":"PF Brunsvig","year":"2020","unstructured":"Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, et al. Long-term outcomes of a phase I study with UV1, a second generation telomerase based vaccine, in patients with advanced non-small cell lung cancer. Front Immunol. 2020;11:572172. https:\/\/doi.org\/10.3389\/fimmu.2020.572172.","journal-title":"Front. Immunol"},{"issue":"1","key":"1856_CR324","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/1078-0432.CCR-15-1265","volume":"22","author":"M Noguchi","year":"2016","unstructured":"Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S, et al. An open-label, randomized phase II trial of personalized peptide vaccination in patients with bladder cancer that progressed after platinum-based chemotherapy. Clin Cancer Res. 2016;22(1):54\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1265.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1856_CR325","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s43018-025-00966-7","volume":"6","author":"M Saxena","year":"2025","unstructured":"Saxena M, Anker JF, Kodysh J, O\u2019donnell T, Kaminska AM, Meseck M, et al. Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial. Nat Cancer. 2025;6(6):988\u201399. https:\/\/doi.org\/10.1038\/s43018-025-00966-7.","journal-title":"Nat Cancer"},{"key":"1856_CR326","doi-asserted-by":"publisher","unstructured":"Hillemanns P, Zikan M, Forget F, Denys HG, Baurain J-F, Rob L, et al. Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study. J ImmunoTher Cancer. 2025;13(1):e010827. https:\/\/doi.org\/10.1136\/jitc-2024-010827.","DOI":"10.1136\/jitc-2024-010827"},{"issue":"12","key":"1856_CR327","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S1470-2045(20)30486-1","volume":"21","author":"JW Youn","year":"2020","unstructured":"Youn JW, Hur SY, Woo JW, Kim Y-M, Lim MC, Park SY, et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol. 2020;21(12):1653\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(20)30486-1.","journal-title":"The Lancet Oncol"},{"issue":"23","key":"1856_CR328","doi-asserted-by":"publisher","first-page":"6405","DOI":"10.1158\/1078-0432.CCR-21-1579","volume":"27","author":"DL Cecil","year":"2021","unstructured":"Cecil DL, Liao JB, Dang Y, Coveler AL, Kask A, Yang Y, et al. Immunization with a plasmid DNA vaccine encoding the N-terminus of insulin-like growth factor binding protein-2 in advanced ovarian cancer leads to high-level type I immune responses. Clin Cancer Res. 2021;27(23):6405\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1579.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"1856_CR329","doi-asserted-by":"publisher","first-page":"5162","DOI":"10.1158\/1078-0432.CCR-20-0945","volume":"26","author":"CE Kyriakopoulos","year":"2020","unstructured":"Kyriakopoulos CE, Eickhoff JC, Ferrari AC, Schweizer MT, Wargowski E, Olson BM, et al. Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer. Clin Cancer Res. 2020;26(19):5162\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0945.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1856_CR330","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2024;30(4):1013\u201322. https:\/\/doi.org\/10.1038\/s41591-024-02851-9.","journal-title":"Nat Med"},{"issue":"8","key":"1856_CR331","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong S-J, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2022;28(8):1619\u201329. https:\/\/doi.org\/10.1038\/s41591-022-01937-6.","journal-title":"Nat Med"},{"issue":"10427","key":"1856_CR332","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(23)02268-7.","journal-title":"Lancet"},{"key":"1856_CR333","doi-asserted-by":"publisher","unstructured":"Wang B, Liang Y, Wu Y, Li Q, Zeng Y, Liu L, et al. Sintilimab plus HPV vaccine for recurrent or metastatic cervical cancer. J ImmunoTher Cancer. 2024;12(11):e009898. https:\/\/doi.org\/10.1136\/jitc-2024-009898.","DOI":"10.1136\/jitc-2024-009898"},{"key":"1856_CR334","doi-asserted-by":"publisher","unstructured":"Bilusic M, McMahon S, Madan RA, Karzai F, Tsai Y-T, Donahue RN, et al. Phase I study of a multitargeted recombinant Ad5 PSA\/MUC-1\/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). J ImmunoTher Cancer. 2021;9(3):e002374. https:\/\/doi.org\/10.1136\/jitc-2021-002374.","DOI":"10.1136\/jitc-2021-002374"},{"issue":"8","key":"1856_CR335","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1001\/jamaoncol.2015.2736","volume":"1","author":"CR Heery","year":"2015","unstructured":"Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, et al. Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial. JAMA Oncol. 2015;1(8):1087\u201395. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2736.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1856_CR336","doi-asserted-by":"publisher","first-page":"10609","DOI":"10.1038\/s41467-025-66092-1","volume":"16","author":"S Kucukcelebi","year":"2025","unstructured":"Kucukcelebi S, van \u2018t Land FR, van der Burg SH, Eskens FALM, Homs MYV, Willemsen M, et al. REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. Nat Commun. 2025;16(1):10609. https:\/\/doi.org\/10.1038\/s41467-025-66092-1.","journal-title":"Nat Commun"},{"issue":"1","key":"1856_CR337","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13045-025-01661-x","volume":"18","author":"ZN Berneman","year":"2025","unstructured":"Berneman ZN, De Laere M, Germonpr\u00e9 P, Huizing MT, Willemen Y, Lion E, et al. WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome. J Hematol Oncol. 2025;18(1):9. https:\/\/doi.org\/10.1186\/s13045-025-01661-x.","journal-title":"J Hematol Oncol"},{"key":"1856_CR338","doi-asserted-by":"publisher","unstructured":"Dorff T, Hirasawa Y, Acoba J, Pagano I, Tamura D, Pal S, et al. Phase ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. J ImmunoTher Cancer. 2021;9(8):e002931. https:\/\/doi.org\/10.1136\/jitc-2021-002931.","DOI":"10.1136\/jitc-2021-002931"},{"issue":"10","key":"1856_CR339","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-19-2427","volume":"26","author":"RA Figlin","year":"2020","unstructured":"Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DYT, Master V, et al. Results of the ADAPT phase 3 study of rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2020;26(10):2327\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2427.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1856_CR340","doi-asserted-by":"publisher","first-page":"2379864","DOI":"10.1080\/21645515.2024.2379864","volume":"20","author":"CL Wiseman","year":"2024","unstructured":"Wiseman CL, Holmes JP, Calfa C, Dakhil SR, Bhattacharya S, Peoples GE, et al. Results of a phase I\/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (bria-IMT) in metastatic breast cancer. Hum Vaccines Immunotherapeutics. 2024;20(1):2379864. https:\/\/doi.org\/10.1080\/21645515.2024.2379864.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"19","key":"1856_CR341","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","volume":"26","author":"AA Wu","year":"2020","unstructured":"Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, et al. A phase II study of allogeneic GM-CSF\u2013transfected pancreatic tumor vaccine (GVAX) with Ipilimumab as maintenance treatment for metastatic pancreatic cancer. Clin Cancer Res. 2020;26(19):5129\u201339. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1025.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1856_CR342","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1001\/jama.2014.13943","volume":"312","author":"FS Hodi","year":"2014","unstructured":"Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014;312(17):1744\u201353. https:\/\/doi.org\/10.1001\/jama.2014.13943.","journal-title":"JAMA"},{"issue":"1","key":"1856_CR343","doi-asserted-by":"publisher","first-page":"7880","DOI":"10.1038\/s41467-026-74711-8","volume":"17","author":"HH Wang","year":"2026","unstructured":"Wang HH, Huff AL, Haldar SD, Berg M, Thoburn C, Heumann TR, et al. Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial. Nat Commun. 2026;17(1):7880. https:\/\/doi.org\/10.1038\/s41467-026-74711-8.","journal-title":"Nat Commun"},{"issue":"1","key":"1856_CR344","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40164-025-00703-x","volume":"14","author":"E Fernandez","year":"2025","unstructured":"Fernandez E, Vernet R, Urwyler M, Von Rohr O, Charrier E, Belkouch M-C, et al. Overall survival of recurrent\/metastatic head & neck squamous cell carcinoma patients progressing after \u2265 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11\/16, a phase IIa trial. Exp Hematol Oncol. 2025;14(1):113. https:\/\/doi.org\/10.1186\/s40164-025-00703-x.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"1856_CR345","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/2159-8290.CD-18-1495","volume":"9","author":"SE Bentebibel","year":"2019","unstructured":"Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, et al. A first-in-human study and biomarker analysis of NKTR-214, a novel IL2R\u03b2\u03b3-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Discov. 2019;9(6):711\u201321. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1495.","journal-title":"Cancer Discov"},{"issue":"4","key":"1856_CR346","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41416-025-03069-3","volume":"133","author":"GM Kim","year":"2025","unstructured":"Kim GM, Kim S, Lee MA, Byun M-S, Choi D, Yang SH, et al. GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8+\/CD4+ T cells and TILs in patients with locally advanced or metastatic solid tumours. Br J Cancer. 2025;133(4):524\u201332. https:\/\/doi.org\/10.1038\/s41416-025-03069-3.","journal-title":"Br J Cancer"},{"issue":"3","key":"1856_CR347","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2326-6066.CIR-25-0880","volume":"14","author":"A Liu","year":"2026","unstructured":"Liu A, Johnson C, Niedzwiecki D, Relation T, Yarlagadda SV, Gajewski TF, et al. Phase II trial of interleukin-12 followed by interferon alfa-2b in patients with metastatic malignant melanoma: results from CALGB 500001 (alliance). Cancer Immunol Res. 2026;14(3):423\u201333. https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-0880.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1856_CR348","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00262-026-04307-0","volume":"75","author":"G Batist","year":"2026","unstructured":"Batist G, Kavan P, Augustin L, Schottel J, Moradian J, Lee JT, et al. A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer. Cancer Immunol Immunother: CII. 2026;75(2):60. https:\/\/doi.org\/10.1007\/s00262-026-04307-0.","journal-title":"Cancer Immunol Immunother: CII"},{"issue":"9","key":"1856_CR349","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1038\/s41591-024-03086-4","volume":"30","author":"H Ebrahimi","year":"2024","unstructured":"Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, et al. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2024;30(9):2576\u201385. https:\/\/doi.org\/10.1038\/s41591-024-03086-4.","journal-title":"Nat Med"},{"issue":"7","key":"1856_CR350","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.cell.2025.02.002","volume":"188","author":"Z Chang","year":"2025","unstructured":"Chang Z, Guo X, Li X, Wang Y, Zang Z, Pei S, et al. Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization. Cell. 2025;188(7):1842\u201357.e20. https:\/\/doi.org\/10.1016\/j.cell.2025.02.002.","journal-title":"Cell"},{"key":"1856_CR351","doi-asserted-by":"publisher","unstructured":"Xie XT, Guan M, Cheng K, Li Y, Zhang B, Zhou Y-T, et al. Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy. Sci Adv. 2025;11(13):eadt7298. https:\/\/doi.org\/10.1126\/sciadv.adt7298.","DOI":"10.1126\/sciadv.adt7298"},{"issue":"3","key":"1856_CR352","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley DA. Nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013;170(3):365\u201372. https:\/\/doi.org\/10.1016\/j.jconrel.2013.05.041.","journal-title":"J Control Release"},{"key":"1856_CR353","doi-asserted-by":"publisher","first-page":"168995","DOI":"10.1016\/j.cej.2025.168995","volume":"524","author":"X Yi","year":"2025","unstructured":"Yi X, Tao J, Chen Y, Yuan Y, Teng Z, Li P, et al. Stiffness-transformable photoimmune nanostimulators for remodeling tumor microenvironment of osteosarcoma and inhibiting lung metastasis. Chem Eng J. 2025;524:168995. https:\/\/doi.org\/10.1016\/j.cej.2025.168995.","journal-title":"Chem Eng J"},{"key":"1856_CR354","doi-asserted-by":"publisher","first-page":"114480","DOI":"10.1016\/j.jconrel.2025.114480","volume":"390","author":"H Kong","year":"2026","unstructured":"Kong H, Wang S, Zhuo C, Zhong Q, Xu Y, Lao Y-H, et al. Nanovesicles integrating PD-1-mediated targeting and CRISPR\/Cas9-based CD47 editing for dual immune checkpoint blockade. J Control Release. 2026;390:114480. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114480.","journal-title":"J Control Release"},{"issue":"33","key":"1856_CR355","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1200\/JCO-25-01346","volume":"43","author":"MK Wong","year":"2025","unstructured":"Wong MK, Milhem MM, Sacco JJ, Michels J, In GK, Mu\u00f1oz Couselo E, et al. RP1 combined with nivolumab in advanced anti\u2013PD-1\u2013failed melanoma (IGNYTE). J Clin Oncol. 2025;43(33):3589\u201399. https:\/\/doi.org\/10.1200\/JCO-25-01346.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1856_CR356","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12916-026-04695-1","volume":"24","author":"D Ji","year":"2026","unstructured":"Ji D, Fu W, Liu Y, Shen W, Kuang M, Ning Z, et al. First-in-human phase 1\/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC. BMC Med. 2026;24(1):177. https:\/\/doi.org\/10.1186\/s12916-026-04695-1.","journal-title":"BMC Med"},{"issue":"8113","key":"1856_CR357","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41586-026-10404-y","volume":"653","author":"CJ Lord","year":"2026","unstructured":"Lord CJ, Tutt ANJ, Ashworth A. Two decades of PARP inhibitor synthetic lethality in cancer. Nature. 2026;653(8113):41\u201351. https:\/\/doi.org\/10.1038\/s41586-026-10404-y.","journal-title":"Nature"},{"issue":"8011","key":"1856_CR358","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-024-07350-y","volume":"629","author":"S Ferretti","year":"2024","unstructured":"Ferretti S, Hamon J, de Kanter R, Scheufler C, Andraos-Rey R, Barbe S, et al. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers. Nature. 2024;629(8011):443\u201349. https:\/\/doi.org\/10.1038\/s41586-024-07350-y.","journal-title":"Nature"},{"key":"1856_CR359","doi-asserted-by":"publisher","first-page":"103204","DOI":"10.1016\/j.ctrv.2026.103204","volume":"150","author":"ZL Arter","year":"2026","unstructured":"Arter ZL, Shim JSG, Park C, Waliany S, Lim SM, Soo RA. MTAP loss in non\u2013small-cell lung cancer and beyond: therapeutic targeting of the MAT2A\u2013PRMT5 axis. Cancer Treat Rev. 2026;150:103204. https:\/\/doi.org\/10.1016\/j.ctrv.2026.103204.","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"1856_CR360","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-13-2769","volume":"20","author":"NA O\u2019brien","year":"2014","unstructured":"O\u2019brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, et al. Targeting PI3K\/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res. 2014;20(13):3507\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2769.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1856_CR361","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","volume":"69","author":"RA Gatenby","year":"2009","unstructured":"Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res. 2009;69(11):4894\u2013903. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3658.","journal-title":"Cancer Res"},{"issue":"1","key":"1856_CR362","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41467-017-01968-5","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat Commun. 2017;8(1):1816. https:\/\/doi.org\/10.1038\/s41467-017-01968-5.","journal-title":"Nat Commun"},{"issue":"12","key":"1856_CR363","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jamaoncol.2024.4361","volume":"10","author":"JN Sarkaria","year":"2024","unstructured":"Sarkaria JN, Ballman KV, Kizilbash SH, Sulman EP, Giannini C, Friday BB, et al. Efficacy of adding veliparib to temozolomide for patients with MGMT -Methylated Glioblastoma. JAMA Oncol. 2024;10(12):1637\u201344. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4361.","journal-title":"JAMA Oncol"},{"key":"1856_CR364","doi-asserted-by":"publisher","first-page":"103725","DOI":"10.1016\/j.breast.2024.103725","volume":"75","author":"L Orlando","year":"2024","unstructured":"Orlando L, Maiello E, Orditura M, Diana A, Antoniol G, Morritti MG, et al. Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial. Breast. 2024;75:103725. https:\/\/doi.org\/10.1016\/j.breast.2024.103725.","journal-title":"Breast"},{"issue":"1","key":"1856_CR365","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41392-025-02278-9","volume":"10","author":"M Toulmonde","year":"2025","unstructured":"Toulmonde M, Gu\u00e9gan JP, Spalato-Ceruso M, Valentin T, Bahleda R, Peyraud F, et al. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab. Sig Transduct Target Ther. 2025;10(1):202. https:\/\/doi.org\/10.1038\/s41392-025-02278-9.","journal-title":"Sig Transduct Target Ther"},{"issue":"8","key":"1856_CR366","doi-asserted-by":"publisher","first-page":"9760","DOI":"10.1002\/cam4.5696","volume":"12","author":"M Sato","year":"2023","unstructured":"Sato M, Maishi N, Hida Y, Yanagawa-Matsuda A, Alam MT, Sakakibara-Konishi J, et al. Angiogenic inhibitor pre-administration improves the therapeutic effects of immunotherapy. Cancer Med. 2023;12(8):9760\u201373. https:\/\/doi.org\/10.1002\/cam4.5696.","journal-title":"Cancer Med"},{"issue":"12","key":"1856_CR367","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1816714.","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"1856_CR368","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2025.43.16_suppl.4563","volume":"43","author":"Z Liu","year":"2025","unstructured":"Liu Z, Jiang L, Tian L, Liu Z, Zhou Z, Li Z, et al. Final results of a phase 2 study of HDACi chidamide and PD-1 inhibitor for advanced urothelial carcinoma after platinum therapy. J Clin Oncol. 2025;43(16_suppl):4563\u20134563. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4563.","journal-title":"JCO"},{"key":"1856_CR369","doi-asserted-by":"publisher","first-page":"114546","DOI":"10.1016\/j.jconrel.2025.114546","volume":"390","author":"S Angeli","year":"2026","unstructured":"Angeli S, Neophytou C, Charalambous A, Voutouri C, Themistokleous P, Stylianopoulos T, et al. Modulating tumor mechanics and vascular barriers to enhance chemotherapy efficacy in pancreatic tumors and melanoma. J Control Release. 2026;390:114546. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114546.","journal-title":"J Control Release"},{"issue":"19","key":"1856_CR370","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-Cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"issue":"11","key":"1856_CR371","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol. 2024;35(11):981\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2241.","journal-title":"Ann Oncol"},{"issue":"1","key":"1856_CR372","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41392-024-02087-6","volume":"9","author":"J Zhong","year":"2024","unstructured":"Zhong J, Fei K, Wu L, Li B, Wang Z, Cheng Y, et al. Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial. Sig Transduct Target Ther. 2024;9(1):369. https:\/\/doi.org\/10.1038\/s41392-024-02087-6.","journal-title":"Sig Transduct Target Ther"},{"issue":"11","key":"1856_CR373","doi-asserted-by":"publisher","first-page":"102423","DOI":"10.1016\/j.xcrm.2025.102423","volume":"6","author":"P Msaouel","year":"2025","unstructured":"Msaouel P, Tannir NM, Meric-Bernstam F, King JM, Voss MH, Cheng JP, et al. Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling. Cell Rep Med. 2025;6(11):102423. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102423.","journal-title":"Cell Rep Med"},{"issue":"2","key":"1856_CR374","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ccell.2025.12.014","volume":"44","author":"Z Fu","year":"2026","unstructured":"Fu Z, Song Y, Liu F, Chen L, Cai S, Cui P, et al. Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer. Cancer Cell. 2026;44(2):405\u201323.e13. https:\/\/doi.org\/10.1016\/j.ccell.2025.12.014.","journal-title":"Cancer Cell"},{"issue":"8","key":"1856_CR375","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1097\/JS9.0000000000001516","volume":"110","author":"J Li","year":"2024","unstructured":"Li J, Kong Z, Qi Y, Wang W, Su Q, Huang W, et al. Single-cell and bulk RNA-sequence identi?ed ?broblasts signature and CD8 + T-cell - ?broblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine learning: bioinformatics multi-omics study. Int J Surg. 2024;110(8):4911\u201331. https:\/\/doi.org\/10.1097\/JS9.0000000000001516.","journal-title":"Int J Surg"},{"issue":"1","key":"1856_CR376","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12943-022-01684-9","volume":"21","author":"T Guo","year":"2022","unstructured":"Guo T, Tang XH, Gao XY, Zhou Y, Jin B, Deng Z-Q, et al. A liquid biopsy signature of circulating exosome-derived mRNAs, miRnas and lncRnas predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer. Mol Cancer. 2022;21(1):216. https:\/\/doi.org\/10.1186\/s12943-022-01684-9.","journal-title":"Mol Cancer"},{"key":"1856_CR377","doi-asserted-by":"publisher","unstructured":"Xu Y, Hu X, Yuan Y, Liu W, Wang J, Yang C, et al. Prediction of lung cancer metastasis risk based on single-cell metabolic profiling of circulating tumor cells. Adv Sci (Weinh). 2025;12(39):e08878. https:\/\/doi.org\/10.1002\/advs.202508878.","DOI":"10.1002\/advs.202508878"},{"issue":"4","key":"1856_CR378","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","volume":"82","author":"S Hwang","year":"2025","unstructured":"Hwang S, Woo S, Kang B, Kang H, Kim JS, Lee SH, et al. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. J Hepatol. 2025;82(4):649\u201357. https:\/\/doi.org\/10.1016\/j.jhep.2024.10.020.","journal-title":"J Hepatol"},{"issue":"25","key":"1856_CR379","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1016\/j.cell.2025.10.020","volume":"188","author":"JRM Black","year":"2025","unstructured":"Black JRM, Karasaki T, Abbott CW, Li B, Veeriah S, Al Bakir M, et al. Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction. Cell. 2025;188(25):7083\u201398.e18. https:\/\/doi.org\/10.1016\/j.cell.2025.10.020.","journal-title":"Cell"},{"issue":"7","key":"1856_CR380","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.ccell.2024.06.003","volume":"42","author":"I Casanova-Salas","year":"2024","unstructured":"Casanova-Salas I, Aguilar D, Cordoba-Terreros S, Agundez L, Brandariz J, Herranz N, et al. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. Cancer Cell. 2024;42(7):1301\u201312.e7. https:\/\/doi.org\/10.1016\/j.ccell.2024.06.003.","journal-title":"Cancer Cell"},{"issue":"1","key":"1856_CR381","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1038\/s41467-024-48200-9","volume":"15","author":"LZ Zhang","year":"2024","unstructured":"Zhang LZ, Yang JG, Chen GL, Xie Q-H, Fu Q-Y, Xia H-F, et al. PD-1\/CD80+ small extracellular vesicles from immunocytes induce cold tumours featured with enhanced adaptive immunosuppression. Nat Commun. 2024;15(1):3884. https:\/\/doi.org\/10.1038\/s41467-024-48200-9.","journal-title":"Nat Commun"},{"issue":"1","key":"1856_CR382","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-025-01689-z","volume":"18","author":"P Yang","year":"2025","unstructured":"Yang P, Li Z, Chen X, Ma C, Han Y, Zhang X, et al. Non-canonical small noncoding RNAs in the plasma extracellular vesicles as novel biomarkers in gastric cancer. J Hematol Oncol. 2025;18(1):39. https:\/\/doi.org\/10.1186\/s13045-025-01689-z.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1856_CR383","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.annonc.2025.03.019","volume":"36","author":"C Valenza","year":"2025","unstructured":"Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, et al. Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis. Ann Oncol. 2025;36(7):726\u201336. https:\/\/doi.org\/10.1016\/j.annonc.2025.03.019.","journal-title":"Ann Oncol"},{"issue":"11","key":"1856_CR384","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga J-Y, de la Motte Rouge T, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022;23(11):1367\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(22)00555-1.","journal-title":"The Lancet Oncol"},{"key":"1856_CR385","doi-asserted-by":"publisher","unstructured":"Wu Z, Wu D, Chen Q, Kong W, Wang X, Zhang J, et al. Efficacy prediction and prognostic analysis on immunotherapy and TKIs combination treated mRCC by customized tumor-informed ctDNA-MRD. J Clin Oncol. 2025;43(16_suppl):e16513\u201316513. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e16513.","DOI":"10.1200\/JCO.2025.43.16_suppl.e16513"},{"issue":"1","key":"1856_CR386","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40779-025-00679-z","volume":"12","author":"Y Wang","year":"2026","unstructured":"Wang Y, Xiang YB, Chen XW, Zhang T, Wang J-Y, Liu W-Y, et al. PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer. Mil Med Res. 2026;12(1):94. https:\/\/doi.org\/10.1186\/s40779-025-00679-z.","journal-title":"Mil Med Res"},{"issue":"1","key":"1856_CR387","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41588-020-00750-6","volume":"53","author":"XY Woo","year":"2021","unstructured":"Woo XY, Giordano J, Srivastava A, Zhao Z-M, Lloyd MW, de Bruijn R, et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet. 2021;53(1):86\u201399. https:\/\/doi.org\/10.1038\/s41588-020-00750-6.","journal-title":"Nat Genet"},{"issue":"21","key":"1856_CR388","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/0008-5472.CAN-24-5023","volume":"85","author":"AL Rinkenbaugh","year":"2025","unstructured":"Rinkenbaugh AL, Qi Y, Cai S, Shao J, Baameur Hancock F, Jeter-Jones SL, et al. An annotated biobank of triple-negative breast cancer patient-derived xenografts features treatment-na\u00efve and longitudinal samples during neoadjuvant chemotherapy. Cancer Res. 2025;85(21):4062\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-5023.","journal-title":"Cancer Res"},{"issue":"1","key":"1856_CR389","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-024-03053-4","volume":"43","author":"T Xu","year":"2024","unstructured":"Xu T, Li X, Zhao W, Wang X, Jin L, Feng Z, et al. SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis. J Exp Clin Cancer Res: CR. 2024;43(1):126. https:\/\/doi.org\/10.1186\/s13046-024-03053-4.","journal-title":"J Exp Clin Cancer Res: CR"},{"issue":"6","key":"1856_CR390","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.gastro.2023.01.041","volume":"164","author":"J Wang","year":"2023","unstructured":"Wang J, Yu H, Dong W, Zhang C, Hu M, Ma W, et al. N6-Methyladenosine\u2013Mediated up-regulation of FZD10 regulates liver cancer stem Cells\u2019 properties and lenvatinib resistance through WNT\/\u03b2-catenin and hippo signaling pathways. Gastroenterology. 2023;164(6):990\u20131005. https:\/\/doi.org\/10.1053\/j.gastro.2023.01.041.","journal-title":"Gastroenterology"},{"issue":"3","key":"1856_CR391","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41417-025-00878-9","volume":"32","author":"Y Mao","year":"2025","unstructured":"Mao Y, Hu Y, Meng H, Qin J, An Q, Zhang C, et al. FXYD5 regulates gastric cancer cell metastasis and drug resistance by EMT modulation. Cancer Gene Ther. 2025;32(3):318\u201326. https:\/\/doi.org\/10.1038\/s41417-025-00878-9.","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"1856_CR392","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1158\/2159-8290.CD-24-0556","volume":"16","author":"M Avolio","year":"2026","unstructured":"Avolio M, Leto SM, Sassi F, Lupo B, Grassi E, Catalano I, et al. The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancer. Cancer Discov. 2026;16(2):270\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0556.","journal-title":"Cancer Discov"},{"key":"1856_CR393","doi-asserted-by":"publisher","unstructured":"Wang H, Shi JZ, Zhu X, Wang L. Next-generation sequencing complemented with mini patient-derived xenografts to guide individualized treatment for patients with aggressive-variant prostate cancer. J Clin Oncol. 2025;43(16_suppl):e17051\u201317050. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e17050.","DOI":"10.1200\/JCO.2025.43.16_suppl.e17050"},{"issue":"1","key":"1856_CR394","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40880-018-0323-y","volume":"38","author":"P Zhao","year":"2018","unstructured":"Zhao P, Chen H, Wen D, Mou S, Zhang F, Zheng S. Personalized treatment based on mini patient-derived xenografts and WES\/RNA sequencing in a patient with metastatic duodenal adenocarcinoma. Cancer Commun. 2018;38(1):54. https:\/\/doi.org\/10.1186\/s40880-018-0323-y.","journal-title":"Cancer Commun"},{"issue":"13","key":"1856_CR395","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1158\/0008-5472.CAN-23-1349","volume":"84","author":"BS White","year":"2024","unstructured":"White BS, Woo XY, Koc S, Sheridan T, Neuhauser SB, Wang S, et al. A pan-cancer patient-derived xenograft histology image repository with genomic and pathologic annotations enables deep learning analysis. Cancer Res. 2024;84(13):2060\u201372. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1349.","journal-title":"Cancer Res"},{"issue":"14","key":"1856_CR396","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.3390\/cancers15143695","volume":"15","author":"C Yan","year":"2023","unstructured":"Yan C, Nebhan CA, Saleh N, Shattuck-Brandt R, Chen S-C, Ayers GD, et al. Generation of orthotopic patient-derived xenografts in humanized mice for evaluation of emerging targeted therapies and immunotherapy combinations for melanoma. Cancer. 2023;15(14):3695. https:\/\/doi.org\/10.3390\/cancers15143695.","journal-title":"Cancers"},{"issue":"8","key":"1856_CR397","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.7150\/thno.100295","volume":"15","author":"X Qin","year":"2025","unstructured":"Qin X, Zhou K, Dong L, Yang L, Li W, Chen Z, et al. CRISPR screening reveals ZNF217 as a vulnerability in high-risk B-cell acute lymphoblastic leukemia. Theranostics. 2025;15(8):3234\u201356. https:\/\/doi.org\/10.7150\/thno.100295.","journal-title":"Theranostics"},{"issue":"1","key":"1856_CR398","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13058-025-02063-0","volume":"27","author":"S Ryu","year":"2025","unstructured":"Ryu S, Kim HS, Lee S, Yoon S-H, Baek M, Park AY, et al. Anti-cancer drug sensitivity testing and preclinical evaluation of the anti-cancer potential of WEE1 inhibitor in triple-negative breast cancer patient-derived organoids and xenograft models. Breast Cancer Res: BCR. 2025;27(1):113. https:\/\/doi.org\/10.1186\/s13058-025-02063-0.","journal-title":"Breast Cancer Res: BCR"},{"issue":"1","key":"1856_CR399","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1186\/s12967-025-07371-9","volume":"23","author":"J Yang","year":"2025","unstructured":"Yang J, Wu T, Xue F, Gong J, Niu X. TRANSPIRE-DRP: a deep learning framework for translating patient-derived xenograft drug response to clinical patients via domain adaptation. J Transl Med. 2025;23(1):1340. https:\/\/doi.org\/10.1186\/s12967-025-07371-9.","journal-title":"J Transl Med"},{"issue":"1","key":"1856_CR400","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13046-025-03629-8","volume":"45","author":"A Farrell","year":"2026","unstructured":"Farrell A, Dall G, Vandenberg CJ, Shield-Artin K, Kyran EL, Blackmore T, et al. High-throughput drug screening identifies EGFR\/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma. J Exp Clin Cancer Res: CR. 2026;45(1):32. https:\/\/doi.org\/10.1186\/s13046-025-03629-8.","journal-title":"J Exp Clin Cancer Res: CR"},{"issue":"2","key":"1856_CR401","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/ph17020225","volume":"17","author":"X Rao","year":"2024","unstructured":"Rao X, Qiao Z, Yang Y, Deng Y, Zhang Z, Yu X, et al. Unveiling epigenetic vulnerabilities in triple-negative breast cancer through 3D organoid drug screening. Pharmaceuticals. 2024;17(2):225. https:\/\/doi.org\/10.3390\/ph17020225.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1856_CR402","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/0008-5472.CAN-25-0608","volume":"86","author":"J Liu","year":"2026","unstructured":"Liu J, Fang F, Yuan W, Chen T, Wang J, Miao X, et al. Integrating ctDNA dynamics and sequential organoid drug screening enhances breast cancer treatment efficacy. Cancer Res. 2026;86(1):182\u201395. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-0608.","journal-title":"Cancer Res"},{"key":"1856_CR403","doi-asserted-by":"publisher","unstructured":"Lee JY, Park M, Kim Y, Sung J, Rheey J, Park JY. The utilization of patient-derived organoids as a platform for predicting the efficacy of anti-cancer drugs: chemotherapy, targeted therapy, and immunotherapy. J Clin Oncol. 2025;43(16_suppl):e15102\u201315102. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e15102.","DOI":"10.1200\/JCO.2025.43.16_suppl.e15102"},{"issue":"1","key":"1856_CR404","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12943-025-02479-4","volume":"24","author":"F Dabbagh Moghaddam","year":"2025","unstructured":"Dabbagh Moghaddam F, Anvar A, Ilkhani E, Dadgar D, Rafiee M, Ranjbaran N, et al. Advances in engineering immune\u2013tumor microenvironments on-a-chip: integrative microfluidic platforms for immunotherapy and drug discovery. Mol Cancer. 2025;24(1):271. https:\/\/doi.org\/10.1186\/s12943-025-02479-4.","journal-title":"Mol Cancer"},{"issue":"4","key":"1856_CR405","doi-asserted-by":"publisher","first-page":"045003","DOI":"10.1088\/1758-5090\/adf099","volume":"17","author":"J Jin","year":"2025","unstructured":"Jin J, Chen W, Li J, Yang J, Dai R, Tang J, et al. Engineered tumor microspheres via microfluidics and decellularized extracellular matrix for high-throughput organoid-based drug screening. Biofabrication. 2025;17(4):045003. https:\/\/doi.org\/10.1088\/1758-5090\/adf099.","journal-title":"Biofabrication"},{"key":"1856_CR406","doi-asserted-by":"publisher","unstructured":"Lavickova B, Kronabitter H, Cervera-Negueruela M, Ceylan E, Benito-Zarza L, L\u00f3pez-Sandoval R, et al. Integrated microfluidic platform for high-throughput generation of intestinal organoids in hydrogel droplets. Adv Sci (Weinh). 2026;13(13):e16507. https:\/\/doi.org\/10.1002\/advs.202516507.","DOI":"10.1002\/advs.202516507"},{"issue":"8","key":"1856_CR407","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.3390\/ijms27083423","volume":"27","author":"AECD Lima","year":"2026","unstructured":"Lima AECD, Nunes M, Xavier CPR, Ricardo S. Re-thinking pharmacokinetics in ovarian cancer: what do organoids add? Int J Mol Sci. 2026;27(8):3423. https:\/\/doi.org\/10.3390\/ijms27083423.","journal-title":"IJMS"},{"key":"1856_CR408","doi-asserted-by":"publisher","unstructured":"Li X, Ren W, Liu L, Liu C, Chen X. A critical reassessment of tumor metastasis simulation in murine models: insights into methodological advances and biological relevance. Adv Ther. 2025;8(12):e00277. https:\/\/doi.org\/10.1002\/adtp.202500277.","DOI":"10.1002\/adtp.202500277"},{"issue":"1","key":"1856_CR409","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059.","journal-title":"Cancer Discov"},{"issue":"1","key":"1856_CR410","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12943-025-02426-3","volume":"24","author":"J Le","year":"2025","unstructured":"Le J, Dian Y, Zhao D, Guo Z, Luo Z, Chen X, et al. Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment. Mol Cancer. 2025;24(1):221. https:\/\/doi.org\/10.1186\/s12943-025-02426-3.","journal-title":"Mol Cancer"},{"issue":"15","key":"1856_CR411","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-25-0999","volume":"85","author":"EA Oliveira","year":"2025","unstructured":"Oliveira EA, Milite S, Fernandez-Mateos J, Cresswell GD, Yara-Romero E, Vlachogiannis G, et al. Epigenetic heritability of cell plasticity drives cancer drug resistance through a one-to-many genotype-to-phenotype paradigm. Cancer Res. 2025;85(15):2921\u201338. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-0999.","journal-title":"Cancer Res"},{"issue":"1","key":"1856_CR412","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-025-02328-2","volume":"11","author":"Y Liang","year":"2026","unstructured":"Liang Y, Chen WM, Zhang Y, Li L. Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis. Sig Transduct Target Ther. 2026;11(1):1. https:\/\/doi.org\/10.1038\/s41392-025-02328-2.","journal-title":"Sig Transduct Target Ther"},{"issue":"5","key":"1856_CR413","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"JC Beltra","year":"2020","unstructured":"Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, et al. Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020;52(5):825\u201341.e8. https:\/\/doi.org\/10.1016\/j.immuni.2020.04.014.","journal-title":"Immunity"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01856-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01856-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01856-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:02:15Z","timestamp":1792548135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01856-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":413,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1856"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01856-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"26 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"90"}}